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Several lines of evidence indicate that neuromuscular junction (NMJ) 
destruction and disassembly is an early phenomenon in the amyotrophic lateral 
sclerosis (ALS) neurodegenerative disease. Here we analyzed by confocal and 
electron microscopy the NMJ structure in the diaphragm of Superoxide 
dismutase (SOD)1 G93A mice at symptom onset and we compared these 
observation with animals sacrificed at the pathological end stage. In young 
transgenic mice, which provide a model for familial ALS, the present findings 
showed marked denervation both in the diaphragm and in the gastrocnemius, 
which partially spares soleus muscle. At the clinical end stage even the soleus is 
slight denervated, but less severely than other muscles. In addition, the size of 
the synaptic vesicle (SV) pool was found reduced and alterations of 
mitochondria were observed in approximately 40% of the remaining presynaptic 
terminals. Treatment of SOD1 G93A mice with the anabolic steroid nandrolone 
during the presymptomatic stage preserved the diaphragm muscle mass and 
features indicative of synaptic activity, represented by the number of vesicles 
docked within 200 nm from the presynaptic membrane and area of acetylcholine 
receptor clusters. Furthermore, structural preservation of mitochondria was 
documented in presynaptic terminals, but innervation of diaphragm muscle 
fibers was only slightly increased in nandrolone-treated SOD1-mutant mice. 
Altogether the results point out and define fine structural alterations of 
diaphragm NMJs in the murine model of familial ALS at symptom onset, and 
indicate that nandrolone may prevent or delay structural alterations in NMJ 
mitochondria and stimulate presynaptic activity but does not prevent muscle 
denervation in the disease.  
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2. INTRODUCTION 
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2.1 Amyotrophic lateral sclerosis characteristic 
 
Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease 
involving both upper and lower motoneurons (UMN and LMN) and is characterized by an 
onset delayed in the adulthood and by the selective and progressive loss of motoneurons 
(MNs) in the in spinal cord, in brainstem and in motor cortex except for the neurons that 
control the bladder, and the oculomotoneurons.  
 
ALS is also known as Charcot’s 
Syndrome name that derived from the 
French neurobiologist and physician that 
described for the first time this disease in 
1869, while the conventional name is due 
to the main features of the disease, in 
particular: 
 Amyotrophic derived from the 
atrophy that affects skeletal muscle fibers 
 Lateral refers to the network of 
motor axons that run down both sides of 
the spinal cord  
 Sclerosis is due to the scar tissue 
that remains following degeneration of the 
nerves 
Every year are diagnosed 1 to 3 new cases 
over a population of 100.000 people while 
the prevalence of individuals with ALS is 
almost the same of the incidence value because patients generally live only two to five years 
after the clinical onset/diagnosis. 
 
 ALS is often used to define a spectrum of neurodegenerative disorders (MND) that are 
characterized by progressive degeneration of motoneurons and that include ‘progressive 
muscular atrophy’ or PMA, ‘primary lateral sclerosis’ or PLS, ‘flail arm/leg syndromes’ and 
‘ALS with frontotemporal involvement’. Primary symptoms of these disorders, clinical 
FIG.1 Upper and lower MN and their 
target muscles 
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presentation, rate of progression and prognosis reflect the motoneural subtype which is affect 
at the onset of the disease, even if it is possible that other subtypes will be involved in later 
stages.  
Thus PMA is a pure LMN disease, that involved speech ability and swallowing, flail arm and 
leg are prevalently LMN, PLS is a pure UMN disease while the classical ‘Charcot ALS’ 
shows both upper and lower signs.  
Regarding this point upper motoneurons sings include hyperreflexia, extensor plantar 
response and increased muscular tone, while lower motoneurons sings include weakness, 
muscular wasting (atrophy), hyporeflexia, cramps and fasciculations. In the classical (or 
Charcot’s) ALS both the classes of MN are involved. 
 In some cases also the frontotemporal cortex is affected and patients show in addiction 
to classical MN signs also an impairment of cognitive functions and behavioural alteration 
(Neary et al., 1998).  
It is possible to distinguish inside the total amount of ALS cases two different forms of 
the disease: sporadic forms (sALS) that include 90-95% of all cases while the remaining 5-
10% are due to genetic forms (fALS) of the disease related with mutations in known sites of 
the genome (Musarò, 2010). Despite the phenotype of these two forms is quite the same, 
sporadic forms has their onset 10 years later respect to familial cases (45 in fALS versus 55 in 
sALS). In both forms  is present a slight prevalence in men respect to women. 
The early stage of the disease is characterized by a massive skeletal muscle weakness 
followed by atrophy, accompanied by spasticity phenomena and/or fasciculation, then 
paralysis that is the main feature till the death of patients that occurs within five years of 
clinical onset.  
 
2.11 Sporadic ALS 
  
 The causes of sporadic forms of ALS are still unknown nevertheless it has been 
hypothesized that ALS is a multifactorial-caused disorder in which several conditions and risk 
factors could play an additive role in the pathogenesis of the disease. 
  
Excitotoxicity mediated by excitatory aminoacids 
 
Several lines of evidence implicate glutamatergic toxicity as one of the most important 
cofactor in the neuronal injury in ALS. Excessive stimulation of glutamate receptors causes 
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excitotoxicity. Under physiological conditions, excitotoxicity is prevented by the fast 
clearance of glutamate by the glial glutamate transporters (GLT1) that play a crucial role in 
the regulation of extracellular glutamate concentration. Notably, GLT1 is the major glutamate 
transporter and is widely distributed in the human central nervous system (CNS). The 
selective localization of GLT1 in glial cells has implications for its excitotoxic mechanisms. 
In ALS patients  as well as in animal model (where is expressed the murine homologous 
Excitatory AminoAcid Transporter (EAAT-2)) has been demonstrated that the level of 
expression of the transporter is diminished both in motor cortex and in spinal cords (Van 
Damme et al., 2005). Alterations in this protein might interfere with the normal clearance, 
which allows glutamate to remain in the environment and continue to activate the receptors. 
Once activated, the receptors cause calcium influx that cells are not able to buffer because of 
an insufficient number of calcium-binding proteins. Altered concentration of calcium 
activates apoptotic pathways, which leads to motoneuron death and degeneration. 
 
Oxidative stress and Reactive oxygen species (ROS) production 
 
Physiological activity of living organism needs an appropriate level of ROS for the 
balance of redox status in cells, while high concentration of these reactive species can lead to 
modification and/or inactivation of nucleic acids, proteins and lipids (Zablocka et al., 2008). 
Thus, to cope with injury from oxidative damage and maintain redox homeostasis, aerobic 
organisms have developed efficient defence systems of enzymatic and non-enzymatic 
antioxidants which includes Superoxide dismutase (SOD), Catalase, glutathione system and 
plasma proteins. SOD in particular is able to scavenge superoxide anions produced by the 
cellular metabolism and to convert them in hydrogen peroxide and molecular oxygen.  
There are several evidences that suggest a primary role of oxidative stress in the 
pathogenesis of ALS, both in neurons and in muscle where antioxidant enzyme activity is 
altered. 
Mutations in the SOD1 gene are responsible for 20% of fALS forms but are also highlighted 
in some sALS where the enzyme was able to form proteic aggregates in cellular cytoplasm. 
Dysfunction of one of the most important scavenging system of eukaryotic cells can lead to 
increased oxidative damage, which promotes activation of apoptotic pathways. In SOD1-
caused ALS mitochondrial pool is one of the first targets of degeneration because of the 
presence of ROS induces alteration as membrane depolarization, decreased activity of 
respiratory complexes and cytochrome C release.  
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Mitochondrial pool dysfunction 
 
As mentioned above, there is a clear involvement of mitochondrial pool in the ALS 
pathogenesis. Mitochondria represent a primary site of intracellular production of reactive 
oxygen species, and can activate the apoptosis process through the cytosolic release of 
cytochrome C. Despite numerous reports demonstrating anatomical and functional 
mitochondrial abnormalities associated with ALS, the role of mitochondrial dysfunction in 
disease onset and progression remains unknown. It has been suggested that mutant SOD1 
causes dysfunction and structural damage of mitochondria in human patients and mouse 
models of ALS (Higgins et al., 2003). 
A proposed mechanism suggests that mutant SOD1 is imported into mitochondria, 
where directly causes the damage of the organelle and activation of apoptotic pathway.  
In 2010 Zhou and colleagues indicated that mitochondrial dysfunction, which appears early in 
the course of ALS pathology, does not seem to be restricted to motoneurons, and it is present 
in other tissues, particularly skeletal muscle (Zhou et al., 2010). 
Moreover the damaged mitochondria may contribute to cell death activating the apoptotic 
pathway trough the release of calcium and cytochrome C. 
 
Abnormal proteins aggregation both in MN soma and axons 
 
Common features in neurodegenerative diseases are abnormal protein aggregation and 
formation of inclusion bodies in cells as happened for Alzheimer’s disease, Parkinson and 
polyglutamine diseases as Huntington’s disease. Also in ALS has been observed that 
misfolded and/or polyubiquitinated proteins tend to holigomerize and to form intracellular 
aggregates in motoneurons and, in some cases also in the surrounding glial cell (Bruijn et al., 
1998). Both in sporadic and in familial forms of ALS are found aggregates positive for SOD1 
protein that tends to be misfolded or forms aggregates that in turn trigger a toxic cascade that 
leads to neuronal degeneration. More recently, it has been demonstrated that TAR DNA 
binding protein (TDP)-43 spontaneously forms aggregates (Johnson et al., 2009).  
The C-terminal domain of TDP-43 is crucial for spontaneous aggregation thus several 
ALS-linked TDP-43 mutations within this domain increase the number of TDP-43 aggregates 
and promote toxicity in vivo. Normally, cells are able to sequestrate aberrant proteins into 
inclusions that could be degradated, while, in pathological conditions, such as the increase of 
physiological or environmental stress, the ubiquitin-proteasome system can become 
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overloaded and impaired. This results in engulfment of the cells, which become defective in 
the disposal of altered macromolecules and more prone to damage (Kabashi et al., 2006). 
Moreover the P56S substitution over the gene encoding for VAPB induces the formation of 
insoluble aggregates (Nishimura et al., 2004; Kim et al., 2010), and into these aggregates even 
the WT protein is sequestrated leading to the loss of its Unfolded protein response (UPR)-
associated activity (Prosser et al., 2008; Fasana et al., 2010) 
On the other hands also in motoneuronal axons protein aggregation could exert its effect by 
the formation of ‘spheroid’ (aggregates of neurofilament) in the proximal axons, which slow 
down the axonal transport both the retrograde and the anterograde or block them (axonal 
strangulation). 
  
Inflammation  
 
A common pathological hallmark in ALS is the strong inflammatory reaction, due to 
the presence of ubiquitin-immunoreactive cytoplasmatic inclusions/aggregates (McGeer and 
McGeer, 2002). Both CNS and spinal cords are affected by a diffused gliosis and the 
accumulation of activated microglia that become hypertrophied in the grey matter, while in 
the white matter cells engorged with myelin products, lose their processes and become ‘fat 
granule cells’. Even astrocytes are observed throughout these degenerating areas. Moreover in 
ALS was observed an increased level of expression of cytotoxic species (ROS as mentioned 
above), mediators of inflammation and proinflammatory cytokines. 
 
Viral agents 
 
Over the last years have been reported several cases of ALS or ALS-like disease in 
association with human immunodeficiency virus type 1 (HIV) infection (Verma and Berger, 
2006). Additionally, other forms of motoneuron disease, such as, brachial amyotrophic 
diplegia, have also been observed in HIV infected patients (Berger et al., 2005).  
Higher frequency of ALS syndrome in HIV seropositive population, even if the clinical 
features of these disorders is partially different in term of age of onset and timing of 
progression to classical Charcot’s forms, have been proposed as evidence for the causal 
relationship between the HIV infection and ALS. 
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Acquired causes  
 
Heavy metals exposure is referred as a risk factor for the development of ALS. A 
higher risk related to the report of occupational exposure to lead was observed, while it seems 
to have no effects in terms of occasional exposure.  
In a paper of 2007, it has been shown that although no other assessments were 
performed (genetic, environmental or biologic), the probable aetiology for ALS in some cases 
was exposure to lead (Oh et al., 2007).  
Similarly, acute and chronic intoxication with mercury may cause ALS syndrome. In 
1996 was reported a case of acute intoxication with mercury followed by the appearance, 
three years later of ALS symptoms (Schwarz et al., 1996) possibly explained by the slow 
accumulation of mercury in the CNS, since other acquired causes may have favoured 
retrograde axonal transportation.  
Excessive exposure to selenium has also been reported among the possible aetiologies 
for ALS, with its unknown origin and indicative of severe prognosis. This relation has been 
based on epidemiological investigations, which demonstrate an increase of ALS risk 
associated with the residency in a Selenium-impregnated area or with the consumption of 
water with high inorganic levels of this metal. It has also been shown that selenium, mainly in 
its inorganic form, presents a selective toxicity to motoneurons, with the compromise of 
muscular function in animal models (Vinceti et al., 2010).  
Occupational exposure to pesticides and insecticides are some of the factors associated 
with an ALS development increased risk as reported in a 2006 study on the chronic inhalation 
of pyrethroid insecticides (Doi et al., 2006).  
Moreover, increased post-war risk of ALS has been observed in soldiers who were 
deployed to the Gulf Region during the first Gulf War period, suggesting that the exposure to 
neurotoxins as an environmental risk factor (Horner et al., 2003). 
Several hypotheses have been formulated trying to explain the high incidence of ALS 
among soccer players, including as possible candidates excessive physical activity, drugs and 
doping, dietary supplements, pesticides used on the playgrounds, and traumas to the head and 
to other body parts (Belli and Vanacore, 2005; Chen et al., 2007). 
 Finally has to be mentioned the possible role of dietary factors in sALS pathogenesis, 
as indicated by the high incidence of a malignant ALS form associated with Parkinson-
dementia complex (PDC), that is reported as a consequence of the exposure and ingestion of 
Cycas micronesica (Steele and McGeer, 2008). 
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2.12 Familial ALS 
 
 
   
 
Cu, Zn Superoxide dismutase 1 (SOD1) 
 
SOD1 is an homodimer, codified by a single gene that localizes in 21q22 position, in 
which both the monomers are linked with copper and zinc ions (Gurney et al., 1994).  This 
protein is ubiquitously expressed, with a predominant localization in the cytosol but also in 
mitochondria, peroxisomes and lysosomes (Raimondi et al., 2006; Forsberg et al., 2010) and 
it catalyzes the dismutation of superoxide anion in atoxic products (molecular oxygen and 
hydrogen peroxide).  
SOD1 mutations are responsible for the 20% of familial forms of ALS; the linkage 
between the enzyme and the pathology was discovered at the beginning of ‘90s by Siddique 
and colleagues (Siddique, 1991) while, three years later, has been described the presence of 
several mutations over this gene able to induce an ALS phenotype (Rosen et al., 1993).  
To date over one hundred and forty mutations have been identified in the coding 
region of this gene associated with an ALS phenotype. Almost all mutation are inherited in a 
dominant autosomal manner, D90A substitution is a partial exception because it is a recessive 
in Scandinavian population but it is dominant in others (Robberecht et al., 1996). The enzyme 
is particularly plentiful in the spinal cord and brain, where it has been estimated to comprise 
between 0.1% and 2.0% of the detergent-soluble protein (Pardo et al., 1995). This abundance 
likely reflects the copious superoxide generated by these highly respiring tissues. The 
TAB1. Familial forms of ALS (Ticozzi et al., 2011)  
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fundamental role of SOD1 as an antioxidant protein, combined with its abundance in neural 
tissue, suggested an initial hypothesis that the pathogenic SOD1 mutations might result in an 
enzyme that is unable to detoxify reactive oxygen species. 
Over time, this loss of enzymatic function could lead to oxidative damage and death of 
neural cells. However, mice lacking SOD1 do not develop motoneuron disease (Reaume et 
al., 1996) and transgenic mice expressing human fALS SOD1 mutants in addition to their 
own endogenous SOD1 develop paralytic symptoms strikingly similar to those observed in 
human patients (Bruijn et al., 1997; Gurney et al., 1994). Together, these observations imply 
that pathogenic SOD1 molecules act through the gain of a cytotoxic property and not a loss of 
function. 
 
Alsin (ALS2) 
 
ALS type two is a autosomal recessive form of fALS due to mutation in the gene 
coding for alsin mapping on chromosome 2q33-35. 
Also this juvenile-onset form induces atrophy and weakness of distal skeletal muscles, 
spasticity progressively ascending from the lower limbs to the cervical and bulbar segments. 
The gene for alsin could generate two different splicing isoforms the long and the short one. 
At least 13 different ALS2 mutations have been described so far, the majority of which are 
frame-shift deletions resulting in a prematurely truncated protein, or nonsense mutations. 
Interestingly, it has been observed that the mutations that affect both the long and short form 
of the protein result in the juvenile ALS phenotype, while those that alter only the long form 
are responsible for the milder phenotypes of juvenile primary lateral sclerosis or infantile-
onset ascending hereditary spastic paraparesis, both characterized by an isolated involvement 
of the corticospinal tracts (Kress et al., 2005; Eymard-Pierre et al., 2006; Panzeri et al., 2006). 
Alsin localizes to the cytosolic face of endosomal membranes and acts as a guanine 
nucleotide exchange factor for Rab5 and other small GTPases (Otomo et al., 2003). It is 
thought to be involved in vesicular trafficking, cytoskeletal organization, and endosomal 
dynamics. The fact that all ALS2 pedigrees are homozygous, and the observation that 
mutations lead to protein instability suggests that the loss of the physiological functions of 
alsin leads to ALS (Yamanaka et al., 2003). It must however be noticed that ALS2 knockout 
mice do not develop motoneuron disease (Cai et al., 2005). 
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Sentaxin (SETX) 
 
ALS4 is a slow progression motoneuron disease with a autosomal-recessive 
inheritance and an early onset in the adulthood. Patients usually develop symmetrical 
weakness and atrophy of the distal muscles of the limbs in their second decade. The 
phenotype is characterized by the involvement of the corticospinal tracts, while bulbar 
muscles are consistently spared (Chance et al., 1998). It has been found that ALS4, initially 
linked to the chromosome 9q34, is caused by mutations in the SETX gene (Chen et al., 2004) 
that encodes for sentaxin. 
To date, only four SETX mutations have been identified, and all of them are missense 
substitutions (Chen et al., 2004; Zhao et al., 2009). 
Sentaxin is a ubiquitously expressed DNA/RNA helicase, possibly involved in 
repairing DNA double-strand breaks following oxidative stress (Suraweera et al., 2007). 
Moreover, it has been shown to bind RNA polymerase II and other proteins involved in 
mRNA transcription and processing, suggesting that it is involved in transcriptional 
regulation (Suraweera et al., 2009). 
 
Spatacsin (SPG11) 
 
ALS5 is another recessive form of fALS with an early onset and it is characterized by 
distal muscle atrophy and weakness associated with pyramidal signs and involvement of 
bulbar muscles. The disease has been mapped to a locus on chromosome 15q15- 21 (Hentati 
et al., 1998). Recently, are identified 12 homozygous, or compound heterozygous, mutations 
in the SPG11 gene in 10 unrelated pedigrees (Orlacchio et al., 2010). The majority of the 
identified variants are frame-shift mutations or nonsense substitutions. Homozygous 
mutations in the same gene have been previously described in patients with autosomal 
recessive hereditary spastic paraplegia with thin corpus callosum (Stevanin et al., 2007). In a 
single case, a post-mortem examination revealed pathological evidence of neurodegeneration 
in lower motoneurons, although Bunina bodies and ubiquitinated inclusions seem to be 
absent. SPG11 is composed of 40 exons and encodes for the 2443-residue long protein 
spatacsin. The physiological role of spatacsin is still unknown, although it is reputed to be 
involved in axonal transport (Salinas et al., 2008). 
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Fused in sarcoma (FUS) 
The ALS type 6 is a dominant classic fALS linked with the genetic locus on 
chromosome 16p12.1-q21 (Sapp et al., 2003). Recently it has been identified a novel variants 
in the FUS gene (Kwiatkowski et al., 2009; Vance et al., 2009) as the disease-causing 
mutations in ALS6 families that is responsible of about 4% of familial cases of ALS and 
about 1% of sporadic ones (Yamamoto-Watanabe et al., 2010; Yan et al., 2010).  
To date more than 30 different mutations have been described, the vast majority of 
which are missense substitutions and the rest are frame-shift or nonsense mutations.  
Although genotype-phenotype correlations are not possible for the majority of FUS 
mutations, it has been suggested that mutations R521C over this gene may result in an 
uncommon phenotype characterized by a symmetrical and proximal spinal onset, with early 
involvement of the axial muscles (Ticozzi et al., 2009). The FUS gene encodes for a 
DNA/RNA binding protein that is involved in several cellular pathways, including 
transcriptional regulation, maintenance of genomic stability, and splicing, nucleo-cytoplasmic 
shuttling, transport, and maturation of mRNAs (Law et al., 2006). In the central nervous 
system, the protein is involved in regulating mRNA transport towards the dendrites and 
synaptic plasticity upon the activation of glutamate receptors (Fujii et al., 2005).  
The majority of the mutations identified so far are clustered in the region containing 
the nuclear localization signals that could led to a unbalance between nuclear and 
cytoplasmatic forms of FUS protein and the consequent formation of proteic aggregates 
(Vance et al., 2009). 
It has been hypothesized that FUS mutations may contribute to ALS pathogenesis 
through the formation of cytoplasmic  inclusions and/or the loss of the physiological nuclear 
functions of the protein.  
 
Vesicle-associated membrane protein (VAMP)-associated protein B (VAPB) 
 
ALS8 is linked with a locus on chromosome 20q13.33 and has been initially described 
as an autosomal-dominant, slow progressive ALS (Nishimura et al., 2004) Characterized by 
lower motoneuron symptoms, predominantly in the limb muscles. A single patient also 
presented upper motoneuron signs.  
ALS8 is caused by a single mutation, the P56S substitution over the VAPB gene, 
which encodes for the VAMP-associated protein B.  
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The VAPB gene spans 57.7 kb of genomic DNA and it is composed of six exons. 
Through alternative splicing, it gives rise to two proteins of 243 (VAPB) and 99 residues 
(VAPC). VAPB/C are ubiquitously expressed, localize to the endoplasmic reticulum and 
associate with microtubules, suggesting a role in vesicle trafficking (Nishimura et al., 2004; 
Kanekura et al., 2006).  
Since VAPB/C are present as homo or heterodimers it has been hypnotized that the 
P56S mutation exerts a dominant negative effect on the WT protein, in fact, it has been shown 
that P56S-VAPB can form insoluble cytoplasmic inclusions in neural and non-neural cell 
lines, sequestering and co-precipitating WT-VAPB (Suzuki et al., 2009).  
Aggregates formation and the loss of the physiological functions of VAPB may lead to 
motoneuron degeneration. Supporting the latter hypothesis is the observation that the 
silencing of the Drosophila melanogaster Dvap33 gene, homologous to VAPB, leads to 
progressive paralysis of the larvae, formation of cytoplasmic inclusions and 
neurodegeneration. The phenotype is rescued by overexpressing the human VAPB gene (Chai 
et al., 2008). 
 In cellular culture the overexpression of VAPB has a dominant negative effect on the 
WT protein, the P56S mutation has the tendency to holigomerize and to form aggregates in 
the perinuclear zone (Prosser et al., 2008). 
 Previous work in our department indicate that in HeLa cells, transfected transiently 
with VAPB P56S, is possible to observe the formation of aggregates positive for this mutated 
protein (FIG.2), to better clarify the mutation role in the aggregates formation in vivo 
experiment of microinjection were performed and indicate that the clusterization of protein is 
a very fast event (Fasana et al., 2010). 
 
 
(Modified from Fasana et al., 2010) 
FIG.2 HeLa cells 
transiently 
transfected with 
VAPB P56S 
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 Ultastructural analysis of these aggregates indicates a close relationship with the 
surrounding endoplasmic reticulum and that cisternae in transfected cells  (both in HeLa and 
in NSC34) are stacked in structure with a peculiar electron density of the cytosol among a pair 
of cisternae. 
 
 
 
 
 
 Through an EM tomography approach the architecture of these structures has been 
solved, indicating that those structure show continuity both to the nuclear envelope and to 
conventional ER. 
 
 
(In collaboration with A.Raimondi and G. Bertone – IIT – Genova)  
FIG.4 EM 
tomography  of 
VAPBP56S – 
positive aggregate 
in HeLa cells 
Tomogram JEOL 
200 KV  STEM on 
500 nm thick 
section 
 ± 60°- 1° tilt    
 
FIG.3 Ultrastructural characterization of VAPB positive aggregates in HeLa cell line.                                                                            
(modified from Fasana et al., 2010) 
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 The same structures viewed in culture of HeLa (FIG.3) and NSC34 (data not shown) cells 
have been found in spinal cords of transgenic mice carrying the P56S substitution (FIG.5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG.5 Ultrastructural  characterization  of  VAPB  positive  aggregates in the 
spinal cord of transgenic mice. VAPB P56S inclusion were found in semithin 
section and deeper investigate with conventional EM.                                                                  
     (unpublished data) 
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Angiogenin (ANG) 
 
Increasing evidence supports the hypothesis that angiogenic factors may be involved 
in the pathogenesis of ALS. A screening of a large cohort of North European patients reported 
an association between two haplotypes in the vascular endothelial growth factor gene (VEGF) 
promoter and susceptibility to sALS. The deletion of the hypoxia response element in the 
gene promoter and the consequent down-regulation of VEGF expression lead to a progressive 
motoneuron degeneration in mice (Lambrechts et al., 2003).  
In 2004, the rs11701 single nucleotide polymorphism (SNP) in the ANG gene, 
encoding for angiogenin, a downstream effector of VEGF, was shown to be associated to 
sALS susceptibility in the Irish and Scottish populations (Greenway et al., 2004). Direct 
sequencing of the coding regions of ANG in 1629 ALS patients and 1264 controls identified 
seven missense mutations in 15 individuals, of which four were fALS and 11 sALS 
(Greenway et al., 2006).  
The association with rs11701, however, could not be replicated. The identification of a 
large ALS-FTD family in which the K17I mutation segregates with the disease led to the 
designation of all ANG-associated fALS as ALS9 (van Es et al., 2009).  
Angiogenin, a member of the pancreatic ribonuclease superfamily, is expressed 
mainly in hepatocytes and secreted into the serum and the extracellular matrix. After uptaking 
by still unidentified endothelial receptors, the protein is translocated into the nucleolus where 
it stimulates tRNA transcription, ribosome biogenesis, protein translation, and cell 
proliferation (Moroianu et al., 1994; Smith et al., 2006).  
The majority of the 15 mutations described so far is clustered in regions encoding for 
the catalytic site or for the nuclear import signal and are consequently predicted to disrupt 
angiogenin secretion, ribonucleolytic activity and/or nuclear translocation, ultimately 
resulting in impairment angiogenesis (Wu et al., 2007).  
The loss of angiogenin physiological functions may thus lead to motoneuron 
degeneration. In fact, wild-type angiogenin has been shown to protect primary motoneurons 
from hypoxia-induced cell death, while ALS-associated ANG mutants do not.  
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TAR-DNA binding protein (TDP-43)  
 
TDP – 43 is the main component of ubiquitinated cytoplasmic inclusions in ALS 
(Neumann et al. 2006). In aggregates, TDP-43 is hyperphosphorylated and cleaved to 
generate abnormal C-terminal fragments.  
In unaffected neuron the localization of this protein is nuclear while in mutated cells 
there is a nucleo-cytoplasmic redistribution of the protein that colocalizes with inclusions. 
It is not still establish if the pathogenetic role of mutated TDP-43 is due to the loss of 
it physiological localization or to a gain of adverse functions that turns aggregates in 
cytotoxic inclusions (Ticozzi et al., 2010). Mutations in the TARDBP gene, encoding for 
TDP-43, have been consider as the main cause of fALS, because has been identified in 
several populations of different geographic origin (Kabashi et al., 2008; Kuhnlein et al., 2008; 
Van Deerlin et al., 2008; Corrado et al., 2009; Del Bo et al., 2009; Ticozzi et al., 2009; 
Millecamps et al., 2010).  
Mutations over TDP gene are responsible for about 5% of familial ALS and it has 
been find in about 2% sporadic forms. Despite the specific functions of TDP-43 in neuronal 
cells remain to be completely understood, the protein plays a role in several biological 
processes, including gene transcription, splicing regulation, transport and stabilization of 
mRNA molecules (Buratti et al., 2008).  
To date, more than 30 different TARDBP mutations have been described, all of which 
are missense substitutions. With a single exception, all of them are clustered in the C-terminal 
glycine-rich region. Since most TARDBP mutations are private, it is difficult to establish clear 
genotype-phenotype correlation. It has been suggested that A382T, which is the variant most 
commonly observed, may be associated with a predominantly lower motoneuron disease with 
an asymmetrical onset in the distal muscles of the limbs, subsequently spreading to proximal 
muscles, with relative sparing of the bulbar muscles (Corrado et al., 2009). 
 
PI(3,5)P(2)5 – phosphatase (FIG4) 
 
In 2009 ten heterozygous mutations in the FIG4 gene have been identified in six sALS 
and three more fALS patients (Chow et al., 2009). The identified variants include missense 
and nonsense substitutions, mutations at consensus splice sites and frame-shift insertions and 
deletions. Interestingly, two patients had been diagnosed with primary lateral sclerosis, and 
the majority of the others had prominent signs of corticospinal tracts degeneration. The 
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compound heterozygosity of the I41T FIG4 mutation with a nonsense or frame-shift mutation 
had been previously been identified as the genetic cause of the Charcot-Marie-Tooth disease 
type IV, an autosomal recessive neuropathy characterized by an infantile onset and rapid 
progression (Chow et al., 2007).  
FIG4 encodes for a phosphoinositide phosphatase that regulates the synthesis and 
turnover of phosphatidylinositol-3,5-bisphosphate, a molecule that is involved in the 
retrograde transport of endosomal vesicles to the trans-Golgi network (Rutherford et al., 
2006). Interestingly, null mice for FIG4 display widespread neuronal degeneration in sensory 
and autonomic ganglia, motor cortex, striatum, and cerebellum (Chow et al., 2007). 
 
C9ORF72 
 
An intronic expansion in the gene C9ORF72 has been demonstrated to be the 
underlying cause of a familial form of ALS associated to frontotemporal dementia (Renton et 
al., 2011;  Dejesus-Hernandez et al. 2011).  
The linkage between this locus and the risk of development of ALS was already 
known (Ticozzi et al., 2010 and references therein). 
 
2.13 Pharmacological strategies in ALS 
 
At present, there exists neither prophylactic nor curative treatment for ALS and the 
single prescribed anti-glutamatergic drug Rilutek (riluzole) may have a marginal and 
unsatisfactory effect in extending life by a few months (Bensimon et al., 1994). All the other 
therapies are directed against the symptoms. 
 
Excitotoxicity in ALS and therapeutic strategies 
 
To date the only therapy accepted by the Food and Drugs Administration (FDA) in the 
treatment of ALS (both sporadic and familial forms) is the riluzole that inhibits the release of 
glutamate by inactivating voltage-dependent Na
+
 channels on glutamatergic nerve terminals, 
as well as activating a G-protein dependent signal transduction process, thus slowing down 
disease progression and significantly increasing lifespan of patients by a few months (Doble, 
1996). Moreover, riluzole can also block some of the postsynaptic effects of glutamate by 
non-competitive inhibition at NMDA and AMPA receptors (Albo et al., 2004).  
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Several studies underlined that also the clearance of glutamate from neuromuscular 
synapses is diminished in patients with ALS because of the loss of the astroglial glutamate 
transporter EAAT-2 (excitatory amino acid transporter 2), that is of major importance for 
synaptic glutamate reuptake (Rothstein et al., 1995).  
 
Oxidative stress in ALS and therapeutic strategies 
 
The involvement of oxidative stress in ALS is suggested by the observation that 
mutations in the SOD1 gene are responsible for approximately 20% fALS forms, mainly 
inherited with an autosomal dominant trait (Rosen, 1993). Whether oxidative stress is a 
primary cause of pathogenesis in ALS, or is merely a consequence of the disease, has long 
been debated. However, extensive evidence shows increased oxidative damage in spinal cord 
and motor cortex motoneurons (Shaw et al., 1995; Ferrante et al., 1997) in both sporadic and 
SOD1 familial ALS post mortem tissue (Abe et al., 1995; 1997; Beal et al., 1997). 
Mitochondria are implicated in production of oxidative stress, as the major source of 
ROS, and are also targets of ROS, with decreased mitochondrial efficiency caused by 
oxidative damage (Beal, 2002; Lenaz et al., 2002; Genova et al., 2004). Although preclinical 
studies demonstrated a prolonged survival following coenzyme Q10 treatment (Matthews et 
al., 1998), an antioxidant, essential mitochondrial cofactor facilitating electron transfer in the 
respiratory chain, the phase II study in ALS (NCT00243932) showed insufficient promise to 
warrant Phase III testing (Kaufmann et al., 2009). 
Several studies with manganoporphyrin, AEOL 10150, an antioxidant molecule that 
catalytically neutralizes superoxide, hydrogen peroxide and peroxynitrite, and inhibits lipid 
peroxidation (Patel and Day, 1999) have been performed on ALS patients after positive 
results obtained in animal models (Crow et al., 2005).  
Edaravone is a free-radical scavenger is (3-methyl-1-phenyl-2-pyrazolin-5-one, MCI-
186), approved by the Ministry of Health, Labor, and Welfare of Japan in 2001, now widely 
used for the treatment of acute cerebral infarction (Watanabe et al., 1994) for its 
neuroprotective effect against oxidative damage (Shichinohe et al., 2004; Uno et al., 2005). 
Edaravone administered at clinical onset determined a slowing in symptom progression and 
motor neuron degeneration in the ALS mice model (Ito et al., 2008). More recently the 
efficacy of edaravone has been investigated even in ALS patients (Yoshino and Kimura, 
2006). This study suggested that edaravone is safe and may delay the progression of 
functional motor disturbances by reducing oxidative stress in ALS patients. However, the 
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evidence about the effects of edaravone on human ALS patients awaits the publication of the 
results of a phase III clinical trial of ALS, currently ongoing in Japan. 
 
Apoptosis in ALS and therapeutic strategies 
 
Apoptosis mediates the precise and programmed natural death of neurons and is a 
physiologically important process in neurogenesis during maturation therapeutic strategies in 
ALS.  
However, premature apoptosis and/or an aberration in apoptosis regulation is implicated in 
the pathogenesis of neurodegeneration, a multifaceted process involved in several 
neurodegenerative disease, such as Alzheimer, Parkinson, Huntington diseases and ALS 
(Okouchi et al., 2007). 
Valproic acid (VPA) is a histone deacetylase (HDAC) inhibiting drug that promotes gene 
transcription (Kernochan et al., 2005) and inhibits neuronal cell death by counterbalancing 
apoptosis, oxidative stress and glutamate toxicity (Hassel et al., 2001; Morland et al., 2004).  
Based on the finding that VPA and other HDAC inhibitors increased survival in G93A 
SOD1mice (Sugai et al., 2004; Leng et al., 2008), it was performed a Randomized, Double-
Blind, Placebo-Controlled Sequential Clinical Trial of Sodium Valproate in ALS. 
The administration of Minocycline showed very encouraging results in transgenic 
mice trials (Kriz et al., 2002; Van Den Bosch et al., 2002), while, in a multicentre, 
randomized placebo-controlled phase III trial, showed negative results that were faster in the 
minocycline group than in the placebo group (Gordon et al., 2007).  
 
Neuroinflammation in ALS and therapeutic strategies  
 
Inflammation in ALS may be a secondary response to neuronal injury by genetic, 
biochemical, or environmental insults. Inflammatory cells surround degenerating MN 
(Hirano, 1991), leading to the accumulation of proinflammatory cytokines and free radicals 
that likely contribute to neurodegeneration. Therefore, modulation of inflammation might 
reduce cell death.  
Pre-clinical studies on SOD1 G93A mice suggested that anti-inflammatory agents may be 
effective in treating this disease (McGeer and McGeer, 2002). Several reports have 
demonstrated that pro-inflammatory cytokines have a toxic role in the pathogenesis of ALS 
(Kiaei et al., 2006; Wu et al., 2006). Inflammatory cascades contribute to motor neuron death 
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in the spinal cord in the G93A SOD1 transgenic mice, as well as in human ALS patients 
(Kiaei et al., 2006). Proinflammatory cytokines, such as tumor necrosis factor (TNF), are 
upregulated in ALS.  
Thalidomide shows potent anti-inflammatory properties through the modulation of 
inflammatory cytokines such as TNF-α and appreciably penetrates the CNS (Franks et al., 
2004).  In this trial it was demonstrated that thalidomide could cause adverse effects without 
effectively modulating disease progression (Stommel et al., 2009). 
 
Neurotrophic factors in ALS and therapeutic strategies  
 
Neurotrophic factors are involved in the regulation of neuronal survival and 
differentiation and in maintaining neuronal structural integrity. In SOD1 G93A mice 
treatment with insulin-like growth factor (IGF)-1 or glial-cell-line-derived neurotrophic factor 
(GDNF) have beneficial effects on survival and motoneurons morphology, also decreasing 
gliosis (Kaspar et al., 2003; Dobrowolny et al., 2005).   
 
Inhibitors of protein aggregation in ALS and therapeutic strategies 
 
Several neurodegenerative diseases are characterized by the formation of intracellular 
aggregates, that have been described in neuropathological studies of ALS. Moreover, protein 
missfolding and aggregation are peculiar features of both neurodegenerative and 
polyglutamine disease. It has been established that administration of anti-aggregation drugs 
such as sodium butyrate and HDAC inhibitor ameliorated neurological phenotypes in animal 
models of spinal and bulbar muscular atrophy (Minamyama et al., 2004). 
As for mutant SOD1 (mSOD1) transgenic mice sodium phenylbutyrate promotes 
survival of animal and regulates the expression of antiapoptotic genes (Ryu et al., 2005). In 
ALS patients, sodium butyrate is safe and well tolerable, but further clinical trials are required 
(Cudcowicz et al., 2009). 
 
Autophagy inducers 
 
Several targets and signaling pathways regulate autophagy, including the mammalian 
target of rapamycin, mTOR, as a negative regulator. By inhibiting mTOR, rapamycin is 
currently used to upregulate autophagy, and has been shown to be beneficial in models of 
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neurodegenerative diseases (Ravikumar et al., 2004; Berger et al., 2006; Rubinsztein et al., 
2007).  
Results about the ALS treatment with lithium are still contradictory in terms of its 
effect on ALS. Lithium targets different molecules, and acts on different pathways, the final 
effect critically depending on the dose. Defective autophagy has been found in diseased 
motoneurons (Venkatachalam et al., 2008) and when authopagy is blocked in G93A SOD1 
mice, SOD1 accumulates and neuroprotection does not occur (Crippa et al., 2010). Moreover, 
a 15-month pilot clinical trial in randomized ALS patients showed that lithium and riluzole 
cotreatment markedly reduced mortality when compared with matched control patients treated 
with riluzole alone (Fornai et al., 2008). However, inconsistent results have also been 
reported. In a sibling matched, gender-balanced, investigator-blinded trial, using a standard 
mouse model of familial ALS chronic lithium treatment showed no benefit (Gill et al., 2009). 
Another study also found no therapeutic or neuroprotective effects of lithium in female ALS 
mice (Pizzasegola et al., 2009).  
 
2.2 Experimental model of ALS1 
 
Starting from the background knowledge of SOD1 mutations several experimental 
models of ALS type1 were generated and employed in the study of cellular features, 
aetiopathogenetic mechanisms, clinical onset and disease progression, involvement of 
different type of cells as well as in the study of effectiveness of genetic and pharmacologic 
treatments.  
 
Cellular models 
 
Several lines of evidence indicate that, differently of what previously hypothesized, 
ALS is a non-cell autonomous disease (Ilieva et al., 2009).  Thus cultures of isolated MN, or 
motoneuronal cell lines, are an useful tool to the understanding of sub-cellular compartments 
of mutant SOD1-mediated toxicity, they are not sufficient to explain the role of other 
cells/tissues neither in the pathogenesis, nor in the progression. 
Despite this consideration cellular models of ALS1 heve been used for example in the 
investigation of functional and morphological alterations among the mitochondrial pool, 
highliting that mutant SOD1 expression in neuronal cell lines or in primary culture of 
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motoneurons induces mitochondrial depolarization, alteration of calcium homeostasis, 
reduction in ATP production  (reviwed in Pasinelli and Brown, 2006).  
Finally co-culture of MNs and glial cells are useful in the study of cellular survival: 
motoneurons are less likely to survive when they are cultured with astrocytes that express 
mutant SOD1, or exposed to astrocyte-conditioned medium, than on astrocytes that express 
normal SOD1 (Julien, 2007). 
 
Transgenic rodent 
 
The discovery of mutations in SOD1 as a cause of ALS, provided the first opportunity 
to produce a genetically faithful model of the disease. Transgenic mice that overexpress 
human SOD1-harboring mutations linked to fALS develop the usual, fatal, progressive 
neurodegenerative disease seen in human patients. 
 Mutant human SOD1 (hSOD1) genes that have been introduced into mice include 
A4V, the most common and severe ALS-associated mutatation, mutatoins that alter the 
enzymatic function (for example G85R) and mutations that has no effect on its functionality 
(for example G93A).  
The age of clinical onset in mice is higlhly variable, while the duration of illness 
appears to be characteristic to each mutation, as happen even in human, infact in patients with 
the L84V mutation, the average life expectancy is less than 18 months after the onset of 
symptoms, whereas patients harboring the H46R mutation have an average life expectancy of 
18 years after the clinical onset. Thus mutations of SOD1 enzymes acquire toxic properties, 
but, the variations in the duration of illness could be relates with a different degrees of 
toxicity to the mutant protein. In our project we used trnsgenic mice carring the human 
mutation, correlated with familial ALS, SOD1 G93A (Gurney et al., 1994). 
 
Chimeric mice 
 
The restricted expression of the mutated SOD1 (G93A) gene in skeletal muscle is 
sufficient to induce , in trangenic mice, the developement of a progressive muscle atrophy, 
associated with a significant reduction in muscle strength, alterations in the contractile 
apparatus, and mitochondrial dysfunction (Dobrowolny et al., 2008). On the other hand, 
higher levels of expression of the same mutant enzyme (G93A and G37R) in skeletal muscle 
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are shown to induce a distal axonopathy that lead to the degeneration of spinal motorneurons 
(Wong and Martin, 2010). 
The role of glial cells in SOD1–ALS pathogenesis has been examined in chimeric 
mice that were mixtures of normal cells and mutant SOD1-expressing cells (Clement et al., 
2003).  
This study indicated that degeneration of motor neurons expressing mutant SOD1 was 
delayed or prevented when WT non-neuronal cells surrounded them, whereas wild-type motor 
neurons could develop degenerative changes when surrounded by mutant SOD1-expressing 
neuronal cells (Clement et al., 2003). 
 The selective expression of mutant SOD1 in motoneurons (Jaarsma et al., 2008) is 
sufficient to induce ALS like disease but, maybe due to the lower level of expression, it is not 
enough to altered the mitochondrial pool nor to induce the formation of SDO1 aggregates 
both in neurons and glial cells. In particular, it has been demonstrated that, diminishing the 
SOD1 mutant levels in microglia has little effect on the early disease phase, but markedly 
slows later disease progression (Boillée et al., 2006). These results suggest that mutant SOD1 
in microglia contributes to the propagation of disease at a late stage. 
Notably, astrocyte activity normally increases at later stages of ALS disease and is 
concomitant with motor neuron degeneration, which suggests that astrocytes act as deadly 
neighbors that exacerbate motor neuron damage. 
 
2.3 Motor Units (MU) classification, vulnerability and plasticity 
 
Motor units are made by a lower motoneuron and all the muscular fibers it innervates. Several 
parameters have been identified to be responsible for a differential susceptibility to the 
alteration process induced by G93A substitution. These criteria regard both the presynaptic 
and the postsynaptic elements. 
 
Criteria of classification: 
 
Contraction type: 
 
It is generally accepted that muscle fiber types can be divided into two main 
categories: slow twitch (Type I) muscle fibers and fast twitch (Type II) muscle fibers. Fast 
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twitch fibers can be further categorized into Type II a (Fast fatigue-resistant (FR)), Type II b 
(Fast fatigable (FF)) and Type IId/x (Fast fatigue intermediate (FI)) fibers. 
These distinctions seem to influence how muscles respond to training and physical 
activity, and each fiber type is unique in its ability to contract in a certain way. On the other 
hand, muscles with different contraction capability seem to respond differently to pathology 
especially those that induce muscular weakness and wasting (Frey et al., 2000; Kanning et al., 
2010) 
 
Slow Twitch (S – Myosin heavy chain (MHC) class I) 
 
The slow muscles have an oxidative metabolism for continuous, extended muscle 
contractions over a long time. They fire more slowly than fast twitch fibers and can go for a 
long time before they fatigue. Moreover slow fibers are more resistant to the denervation 
process during pathological progression and more plastic (a denervated neuromuscular 
junction (NMJ) could be easily reinnervated or a new junction could be formed in the same 
fiber after the denervation of the old one). 
 
Fast Twitch (F – MHC class II)  
 
Fast fibers have an anaerobic metabolism thus they are much better at generating short 
bursts of strength or speed than slow muscles. However, they fatigue more quickly. Fast 
twitch fibers generally produce the same amount of force per contraction as slow muscles, but 
they get their name because they are able to fire more rapidly. Having more fast twitch fibers 
can be an asset to a sprinter since she needs to quickly generate a lot of force. The faster 
metabolism induces a greater level of ROS production in muscles with a predominance of this 
class of fibers. Moreover those muscles are more sensitive to the denervation and less plastic 
after this process. 
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Synaptogenesis 
 
 
 
 
 
 
Fast synapsing (FaSyn) muscle 
 
In these muscles the synaptogenetic process requires a shorter time than in other 
musclesFaSyn muscles assemble focally organized clusters of cholinergic receptors in the 
absence of nerve, which rapidly become aligned to presynaptic nerve and Schwann cells 
(FIG.6 a). FaSyn muscles could be considered as non-plastic, in fact in this type of  muscles  
NMJs  are lost  rapidly in  SOD1 mice and plastic  processes  of reinnervation are not 
observed  (FIG.6 b). 
    
Delayed Synapsing (DeSyn) muscle 
 
In  these muscles synaptogenesis requires a longer time because cholinergic receptors 
exhibit dispersed microclusters of chinergic receptors between E13.5 and E16.5. During this 
developmental time, nerves and Schwann cells fail to align with AChR microclusters, and 
extensive sprouting is detected (FIG.6a). 
The main evidence of the plasticity response to paralysis or denervation of NMJs in DeSyn 
muscles is the sprouiting process: the blockade of synaptic activity induces ultraterminal 
nerve sprouting, followed by disassembly of the original postsynaptic apparatus and extensive 
collateral sprouting (Santos and Caroni, 2003). 
 
 
 
 
 
FIG. 6 Steps of synaptogenesis in FaSyn and 
DeSyn    muscle    and    their    plasticity    in 
denervation processes. 
(Modified from Santos and Caroni, 2003) 
a) b) 
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2.4 Subcellular targets of motoneuron disease 
 
Presynaptic terminal 
 
Mitochondrial pool 
 
 
 
 
 
 
 
Mitochondrial abnormalities have been found both in cellular and animal model of the 
pathology as well as in ALS patients (Raimondi et al., 2006; Pasinelli et al., 2006). 
Mitochondrial dysfunction in ALS patients includes clusters of abnormal mitochondria and 
morphological defects identified within mitochondria in skeletal muscles and intramuscular 
nerves in human sALS cases (Atsumi, 1981; Afifi et al., 1966). In such cases biochemical 
analyses have delineated defects in the respiratory chain complexes I and IV in muscle 
(Wiedemann et al., 1998) and elevated levels of mitochondrial calcium (Siklós et al., 1996) in 
muscle and spinal cord. In ALS mice, the main morphological evidence for mitochondrial 
pathology is the presence of vacuolated mitochondria (for example, in the G93A and G37R 
transgenic lines).  
In the SOD1 G93A mice, mitochondrial vacuoles derived from a detachment between 
the inner and the outer membrane (FIG.7; Higgins et al., 2003) are evident early, and 
drastically increase in both number and volume as the disease progresses (Kong and Xu, 
1998; Bendotti et al., 2001; Sasaki et al., 2004). 
 
 
 
 
FIG. 7 Patterns of mitochondrial vacuoles: vacuoles are madeby extension of 
mitochondrial outer membrane and expansion of the intermembrane space  
(modified from Higgins et al., 2003) 
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Synaptic vesicles (SV) 
 
Recent studies in different models of MN disease have emphasized early 
morphological abnormalities of NMJ synapses including accumulation of neurofilaments 
(NF) in the presynaptic terminal. Wong and colleagues report that in a spinal muscular 
atrophy (SMA) model that there is NMJ synaptic dysfunction that precedes axonal 
degeneration cellular death (Kong et al., 2009). 
Moreover was documented a reduction in the total number of SV in the presynaptic terminal 
of the NMJ in animal models of ALS with an immunofluorescence. 
 
2.5 ALS is a non-cell autonomous disease 
 
To date, the attempt to understand the pathogenesis of ALS has not given any results, 
there are no consensuses about which cells, tissues and pathways are directly affected by 
mutant SOD1. Several lines of evidence indicate that the causative phenomena inducing MN 
degeneration is a direct consequence of a dominant paracrine activity that emanates from non-
neuronal tissues (Clement et al., 2003). 
The obvious loss of motor neurons in the spinal cord initially focused attention on how 
mutant SOD1 might act within motor neurons to provoke neuronal degeneration and death. 
However, the mutant proteins are ubiquitously expressed, thus the toxicity might result from 
the action of mutant SOD1 in non-neuronal cells. 
Notably, the restricted expression of mutant SOD1 in postnatal motor neurons fails to 
produce detectable signs of pathology or motor neuron disease (Lino et al., 2002), while, 
more recently, has been demonstrated that transgenic mice in which mutant SOD1 was largely 
restricted to neurons, under the transcriptional control of Thy1.2 promoter, developed disease 
only at an old age (Jaarsma et al., 2008). 
However, the disease progressed slowly without reaching the same degree of paralysis 
compared to the classical animal model of ALS in which the same mutant SOD1 gene is 
ubiquitously expressed. Moreover, the analysis of chimeras revealed that the presence of WT 
non-neuronal cells in adult chimeric mice is sufficient to prolong the lifespan of SOD1 mutant 
motor neurons. Although mutant SOD1 is also expressed by muscle, it is not clear whether its 
presence in skeletal muscle directly contributes to any pathological sign of ALS. 
This issue has been recently investigated several group and it has been demonstrated 
that muscle-specific overexpression of mSOD1 induces progressive muscle atrophy 
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(Dobrowolny et al., 2008) and that alteration in skeletal muscles could exert a neurological 
effect on lower MN (Wong and Martin, 2010). These works might explain previous findings 
that have shown how the ubiquitous expression of SOD1 G93A in transgenic mice causes 
first muscle atrophy, which is later followed by alteration of the NMJ, retrograde axonal 
degeneration, and lastly, motor neuron death (Dupuis and Loeffler, 2009).  
The retrograde mechanism of degeneration suggests the possibility that certain muscle 
abnormalities indeed precede motor neuron death rather than result from it. These studies are 
in seem to be in contrast with that reported previously by Miller and colleagues, they found 
that mutant SOD1 does not cause toxicity by its action within the muscle, which suggests that 
muscle is not a primary target for non-cell-autonomous toxicity in familial ALS (Miller et al., 
2006). But the apparent discrepancy can be explained considering that knocking down of the 
protein is not complete and so it is not sufficient to delay the progression of the disease in 
mSOD1 mice: the residual expression of SOD1 G93A mutant gene is able to maintain the 
pathological phenotype 
All the data reported indicate that skeletal muscles play a significant role in the first 
steps of the pathology and it has not a passive role as had been believed up to now. Moreover 
skeletal muscle is also a source of signals that influence neuron survival, axonal growth and 
maintenance of synaptic connections (Funakoshi et al., 1995).  
 
Postsynapting element 
 
Cross sectional area (CSA) 
 
The first clinical symptom of ALS in patients and in animal models is the muscular 
weakness that could be explain through two different mechanisms: 1) the reduction of 
functional motor units because the denervation of fibers; 2) the reduction of CSA of those 
fibers that are still innervated and of those that are reinnervated trough the sprouting of new 
nerve endings (Hegedus et al., 2008; Frey et al., 2000). 
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2.6 Nandrolone decanoate 
 
Anabolic drugs are synthetic analogues of testosterone that exert their action on 
muscle in a complex fashion, via several diverse mechanisms. These processes include 
directly binding to androgen receptors, which then undergo conformational changes and 
translocation into the nucleus to bind to DNA and/or interact with other proteins to regulate 
transcription (Wiegel and Moore, 2007). Other mechanisms include an anti-catabolic effect 
due to interference with glucocorticoid receptor expression, and by activating pathways in the 
CNS, which result in behavioural changes (Kicman, 2008).  
Nandrolone has a higher affinity for androgen receptors than does testosterone 
(Saartok et al., 1984; Bergink et al., 1985). In androgenic tissue, testosterone is converted to a 
more potent metabolite than is nandrolone (Toth and Zakar, 1982; Sundaram et al., 1995). 
Consequently, nandrolone has higher anabolic and lower androgenic effects than testosterone 
(Shahidi, 2001). Nandrolone has been used to prevent muscular weakness and wasting in 
several pathology, such as chronic obstructive pulmonary disease (COPD), in this case its 
effect is more pronounced if associated with inspiratory muscle training (IMT) (Schols et al., 
1995; Creutzberg et al., 2003), osteoporosis (Flicker et al., 1997; Frisoli et al., 2005), chronic 
renal failure (Johansen et al., 2006) and acquired immune deficiency syndrome (Dudgeon et 
al., 2006; Gold et al., 2006). Nandrolone is also the most widespread anabolic steroid used to 
increase muscle mass by athletes and, especially, bodybuilders (Van Marken Lichtenbelt et 
al., 2004). Despite its widespread use, however, the effects and mechanisms of action of 
nandrolone at the cellular level are poorly understood. 
Satellite cells are mononuclear stem cells located between plasmalemma and basal 
lamina of the skeletal muscle fiber (Zammit et al., 2006; Figeac et al., 2007). Satellite cells 
have the ability to become active, proliferate and differentiate into new myonuclei during the 
postnatal maintenance, growth, regeneration or repair of muscle fibers (Kuang and Rudnicki, 
2008). Satellite cell entry into the cell cycle can be stimulated by a variety of influences 
including mechanical stressors, such as exercise or stretch, growth factors and hormones 
(Anderson, 2006; Brack and Rando, 2007). It is thought that satellite cells differentiating into 
myonuclei will maintain the ratio between cytoplasmic volume and number of myonuclei 
(Alway and Siu, 2008). The administration of testosterone, the most widely studied anabolic 
androgenic steroid, has been shown to increase satellite cell numbers in muscle.  
Moreover has been demonstrate that nandrolone could increase the level of expression 
of both mRNA coding for IGF-1 (Gayan Ramirez et al., 2000) and the protein itself (Lewis et 
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al., 2002) in the diaphragm of rats, and that muscle-specific expression of local IGF-1 
stabilizes NMJs in mSOD1 mice (Dobrowolny et al., 2005) delaying disease onset and 
progression.  
In a paper of Bishop and colleagues it has been demonstrate that the effectiveness of 
nandrolone administration is higher in the diaphragm than in all other skeletal muscles 
(Bisschop et al., 1997). 
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3. AIM OF THE PROJECT 
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Amyotrophic lateral sclerosis is a distal axonopathy that begins in the most 
susceptible and specialized point of a motor unit: the neuromuscular junction. 
Over the last years was clarified that both the presynaptic terminals (buttons of 
nerve endings) and the postsynaptic elements (myofibers) are both involved in 
the degeneration of MU. 
What happens later is better described: the nerve terminal retracts in a retrograde 
manner through a dying back process and at the same time the muscle undergoes 
atrophy. 
 
The aim of this process is to characterize the anatomical alterations of the 
components of MUs both at the clinical onset and at the pathological end stage 
to identified any signs of alteration and how this phenomenon change during the 
pathological course. 
 
We chose muscle with different characteristics of resistance, strength and 
plasticity (the soleus, the diaphragm and the gastrocnemius), but we deeper 
analyzed just diaphragm muscles that showed an intermediate response to the 
degeneration, moreover the diaphragm plays a key role in the late stage of ALS 
because patients die to respiratory failure. 
 
The second part of this project is a study of effectiveness of nandrolone 
administration; we investigated again all the morphological and morphometric 
parameters to identify, which were rescued at a control level after the treatment 
with this drug. Nandrolone is already employed in the treatment of pathologies 
characterized by muscular weakness and wasting and it demonstrated to prevent 
atrophy and to improve strength and resistance of skeletal muscle. 
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4. MATERIAL AND METHODS 
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4.1 Animals and procedures 
 
The transgenic mice expressing the human SOD1 gene carrying the G93A substitution 
used in this study belong to the B6SJL-Tg(SOD1*G93A)1Gur/J strain (Gurney et al., 1994) 
and were initially obtained from Jackson Laboratories (Bar Harbor, ME). The transgenic mice 
were genotyped by PCR amplification for the human SOD1 gene, as described elsewhere 
(Kassa et al., 2009). Littermate, non-transgenic B6SJL mice were used as age-matched 
controls. The appearance of muscular weakness sings was evaluated with standard motor tests 
(Paw grip endurance test, Rotarod test). The transgenic mice were also monitored for the 
appearance of tremors and extension reflexes. At P85-P95, first muscular symptoms were 
detected in transgenic mice, at this time point both transgenic and WT littermate were 
sacrificed, after deep anesthesia (chloral hydrate, 600 mg/kg i.p.), with trancardiac perfusion 
with saline solution followed by 4% paraformaldehyde in 0.1M phosphate buffer, pH 7.4 
(PB). The mice used in the analysis of the late stage of the pathology were female mice 
initially obtain from the Jackson Laboratories (Bar Harbor, ME) and belong to the same 
B6SJL-Tg(SOD1*G93A)1Gur/J strain (Gurney et al., 1994). Animals were sacrified at the 
end of 20
th
 week of age (P140). The muscles soleus, diaphragm and gastrocnemius were 
dissected and further fixed by 2 h immersion in the same fixative. The analysis of different 
muscles was aimed, at the comparison of muscles with different fiber composition. The 
muscles were then extensively washed in PB and stored in 0.01M phosphate-buffered saline, 
pH 7.4 (PBS: 0.8% NaCl, 0.02% KCl, 0.144% Na2HPO4, 0.024% KH2PO4), containing 0.5% 
sodium azide at 4°C, until further processing. To prevent alteration due to the chemical 
fixation several samples of soleus and gastrocnemius muscles were dissected and cryo-fixed 
in liquid nitrogen then stored at T -80°.  
Twelve male mSOD1 transgenic mice and wild-type littermates were divided into two 
groups (n= 6 in each group) and treated with either vehicle (NAN-) or nandrolone (NAN+). 
Nandrolone (Nandrolon Vetranal®; Sigma-Aldrich, St. Louis, MO; 10 mg/kg, dissolved in 
peanut oil) was administered once a week by subcutaneous injection, starting at P52 and until 
symptom onset (as determined by the above tests), when the animals were sacrificed.  
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4.2 Fluorescence and Immunofluorescence Analysis  
 
Diaphragm 
 
Small portion of diaphragm close to phrenic nerve were dissected and samples were 
then blocked in 5% Horse Serum, 1% BSA, 1% Triton X-100 in PBS, and then stained with 
1.6% -Bungarotoxin (BuTX) conjugated with tetramethyl-rhodamine (TRITC) (Molecular 
Probes – Invitrogen) in the same blocking solution (BS). 
After the staining, samples positive for BuTX were collected and incubated with the primary 
polyclonal antibody, in these sets of experiments were used both a polyclonal antibody 
directed against Synapsin 1 (a gift from Prof P.De Camilli) (1:400 in BS) or a polyclonal 
antibody direct against Synaptotagmin 1 (SYSY) (1:400 in BS) were used. 
As negative control we used samples in which the step with primary antibody was omitted. 
After three steps in washing solution (WS) (0,5% Triton X-100 in PBS), samples and 
negative controls were incubated with secondary antibody -rabbit conjugated with Alexa 
Fluor 488 (1:200 in WS) (Molecular Probes – Invitrogen). Images were collected using a 
Biorad MRC 1024 confocal laser-scanning microscope and we considered as innervated NMJ 
in which the staining for the presynaptic compartment was present. 
 
Soleus and gastrocnemius  
 
The muscles were embedded in Optimal Cutting Temperature (OCT) and frozen; 20 
m thick cryostat sections of the entire muscle were collected on superfrost ultra plus glass 
slides (Thermo Scientific) and processed for immunolabelling and BuTX labelling as 
described above.  
 
Analysis of acetylcholine receptor clusters 
 
For the evaluation of the total surface and complexity of AChR clusters on the 
postsynaptic membrane, z-stacks of confocal images of NMJs were collected and splitted into 
two classes in relation of their state of innervations.  Then the max projection of NMJ (made 
using the max intensity method) was analyzed with ImageJ software version 1.4. The 
projection was converted into an 8-bit image, upon which a bitmap mask was generated based 
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on the fluorescence intensity threshold. The total area of each NMJ was obtained by adding 
the surface of each fluorescent fragment. 
 
4.3 Transmission electron microscopy (TEM) 
 
For transmission electron microscopy (TEM) analysis, bundles of fibers from control 
and mSOD1 perfused muscles were washed and incubated for 30 min with TRITC-BuTX (15 
mg/ml PBS). Regions of the sample enriched in NMJs, identified with BuTX staining, were 
reduced in size to small segments of 4-5 fibers of 1 mm in length and further fixed with 2% 
glutaraldehyde in 0.1M cacodylate buffer, pH 7.4, and processed with the conventional 
embedding protocol as reported in Francolini et al., 2009. Briefly, the samples were post-
fixed with osmium tetroxide (2% OsO4 in cacodylate buffer), rinsed, en bloc stained with a 
satured solution of uranyl acetate in absolute ethanol, dehydrated and embedded in epoxy 
resin (Epon 812, Electron Microscopy Science, Hatfield, PA), that was baked for 48 h at 
67°C.  
Semithin sections of 0.5 m were obtained with an ultramicrotome (Reichert Ultracut 
E, Leica Microsystems, Austria), collected on glass slides and stained with 0.1% methylene 
blue, 0.1% toluidine blue in PB and observed with an optical microscope with a 60X oil 
immersion objective (Zeiss, Germany). Images were acquired with a CCD Axiocam HR 
(Zeiss); both longitudinal and coronal sections of muscle were used for the evaluation of the 
fiber diameter using the ImageJ software.  
Thin sections and collected on EM copper grids (300 mesh), stained with uranyl 
acetate and lead citrate and examined with a Philips CM10 TEM (FEI, Eindhoven, Holland). 
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4.4 Morphometric analysis at the ultrastructural level 
 
Synaptic vesicle pools 
 
Electron micrographs were acquired with an EPSON perfection 4990 Photo scanner 
(grey scale, 8 bit, 600 ppi, TIF extension) and were used for the evaluation of the total number 
of synaptic vesicles and of their distribution within the presynaptic terminals. 
Each synaptic vesicle has been manually identified with a single pixel point and the 
presynaptic membrane with a ten pixel-thick continuous line. 
Distance between vesicles and active zone were calculated by means of a custom ImageJ 
macro at pixel resolution. 
To automatically find the minimal distance between vesicles and an irregular active zone we 
started from two binary images. The first reported the position of each vesicle centre (the one-
pixel point) whereas the second represented active zones as continuous lines.  
The macro causes expansion of active zone in every direction by pixel dilatation according to 
an octagonal dilatation scheme (Righi et al., 2009). 
The distance of each vesicle was collected when the boundary of the growing line 
superimposed over the vesicle centre. It was then straightforward to build the cumulative 
curve of vesicles in function of their distance. 
Analyzing 3 neuromuscular junctions, we validated the macro, manually and our results were 
compared to ones obtain by the macro. This comparison showed that errors, due to the 
octagonal shape of the expansion, instead of circular, and to sub-pixel distances, were lower 
than 5%. 
A particular tool of the macro allowed to classify vesicular pools by their distance 
from the presynaptic membrane: docked vesicle belonging to readily releasable pool (distance 
lower than 20 nm), vesicles far from 20 to 200 nm and vesicles more distant than 200 nm as 
previously described by Kong and colleagues (Kong et al., 2009). 
 
Mitochondrial pool 
 
Mitochondria of the presynaptic terminal were divided into two classes in terms of 
their morphology state (intact or altered) and in NMJ button were evaluated the density of 
mitochondria, the number of altered profiles and the morphometric parameters of any 
mitochondrion (area and circularity). 
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Digital images were gathered using the same parameters of acquisition that was 
employed for SV micrographs, and analyzed using ImageJ standard tools. 
 
Macro text 
 
/* 
Macro for classification of synaptic vescicle in zones, according to 
distances from a single active zone. Single image version. 
 
Versions. 
v. 1.0 10feb2010 
 
*/ 
 
macro "Vescicle classification" {vesciclass();} 
 
function vesciclass() { 
 requires("1.35b"); 
  
// Definition of interface arrays 
 
 Ingrandimenti = newArray("8900x", "11500x", "15500x", "21000x"); 
 Risoluzione = newArray("300ppi", "600ppi", "1200ppi");  
 Rapporto = newArray("1:1");  
 up = newArray(0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0); 
 limite = newArray(0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0); 
 totves = newArray(0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0); 
 
// User interface for input of image data 
 
 Dialog.create("Settings"); 
 Dialog.addString("Job title?", "",15); 
 Dialog.addMessage("Set magnification and image resolution\n"); 
 Dialog.addChoice("Photo enlargements", Ingrandimenti, 
Ingrandimenti[1]); 
 Dialog.addChoice("Scanner resolution", Risoluzione, Risoluzione[1]); 
 Dialog.addChoice("Pixel X/Y ratio", Rapporto, Rapporto[0]); 
 Dialog.addNumber("Number of zones ", 2,0,3," except the last one"); 
 Dialog.addMessage("\n"); 
 Dialog.show(); 
 Identificativo = Dialog.getString; 
 magni = Dialog.getChoice(); 
 resol = Dialog.getChoice(); 
 ratio = Dialog.getChoice(); 
 nclass = Dialog.getNumber(); 
  
 if (nclass < 1) { 
  exit("You must set at least 1 zone!"); 
 } 
 if (nclass > 25) { 
  exit("No more than 25 zones available!"); 
 } 
 
 Dialog.create("Zone dimensions"); 
 Dialog.addMessage("Max distance from active zone:"); 
 Dialog.addMessage("N.B.: each value must be greater then the previous 
ones!\n"); 
 for (i=1; i<nclass+1; i++) { 
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  Dialog.addNumber("     Zone "+i+" up to: ", 0, 0, 5, 
"nanometers"); 
 } 
 Dialog.addMessage("Final zone for data external to previous zones"); 
 Dialog.show(); 
 for (i=0; i<nclass; i++) { 
  up[i] = Dialog.getNumber(); 
 } 
   
// Calculating pixel dimension 
 
 val_magni = parseInt(replace(magni, "x", "")); 
 val_res = parseInt(replace(resol, "ppi", "")); 
 
 pxdim = 25400000 / (val_res * val_magni); 
 for (i=0; i<nclass; i++) { 
  limite[i] = round(2*up[i]/pxdim); 
  totves[i] = 0; 
 } 
 
// Definitions of variables 
 
 k = 0; 
 r = 0; 
 Initvesc = 0; 
 vestot = 0; 
 ves_actual = 0; 
 
// Recording start time 
 
 getDateAndTime(year, month, week, day, hour, min, sec, msec);  
 mese = month+1; 
 
 setBatchMode(true); 
 
 dir1 = getDirectory("Where would you save the result file?"); 
  
 showMessage("Open input image");  
 open(); 
 
 a=getTitle(); 
 altezza = getHeight(); 
 larghezza = getWidth(); 
 if ((altezza-larghezza) > 0) { 
  totpx = altezza; 
 } 
 else { 
  totpx =larghezza; 
 } 
 results=File.open(dir1+"V_"+a+".txt"); 
 firstline = "Job: "+Identificativo+"\n"; 
 secondline = "Analyzed image: "+a+"\tthe day: 
"+day+"."+mese+"."+year+" at: "+hour+":"+min+":"+sec+"\n\n"; 
 print(results, firstline);  
 print(results, secondline);  
 print(results, "Parameters:\n"); 
 print(results, "Magnification: "+magni+"\n");  
 print(results, "Resolution: "+resol+"\n");  
 print(results, "Pixel dimension: "+pxdim+" nanometri\n");  
 for (i=0; i<nclass; i++) { 
  print(results, "Pixels for "+up[i]+" nanometers: 
"+limite[i]/2+"\t"); 
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 } 
 print(results, "\n"); 
 
 
// Identify vescicle positions 
 
 run("Analyze Particles...", "size=0-1 circularity=0.00-1.00 
show=Masks clear"); 
 rename("V"); 
  
// Identify location of the active zone 
  
 selectWindow(a); 
 run("Analyze Particles...", "size=2-infinity circularity=0.00-1.00 
show=Masks clear"); 
 rename("S"); 
 selectWindow(a); 
 close(); 
  
// Count the number of initial vescicles and write it on file 
  
 selectWindow("V"); 
 run("Analyze Particles...", "size=0-1 circularity=0.00-1.00 
show=Nothing clear record"); 
 Initvesc = nResults; 
 LeftVesc = Initvesc; 
  
 print(results, "Total Initial Vescicles: "+Initvesc+"\n\n");  
  
/* 
Defines the coordinates of the active zone and draws circles with diameter 
equal to settings centered on every pixel of the active zone. Summing all 
the circles we define the area of the zone within x nm from the active 
zone. This step is repeated  for every set limit whereas the external area 
is calculated by difference. 
*/ 
 
 selectWindow("S"); 
 for (i=0; i<nclass; i++) { 
  run("Duplicate...", "title="+i); 
 } 
 
 selectWindow("S"); 
 setThreshold(254,255); 
 run("Create Selection"); 
 
/* 
Given that the Create Selection command define the boundaries of the 
external rectangle we perform a cycle on the selction to find the first 
black pixel. Once found, we select black pixels by magic wand and escape 
from cycles changing cycle limits. 
*/ 
 getSelectionCoordinates(c, d); 
 for (j=d[0]; j<d[2]; j++) { 
  for (i=c[0]; i<c[1]; i++) { 
   if(getPixel(i,j) == 255) { 
    doWand(i,j);       
    i=c[1]; 
    j=d[2]; 
   } 
  } 
 } 
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// The macro gets coordinates of every single pixels of the active zone 
 
 getSelectionCoordinates(xx, yy); 
// Then for every set zone... 
  
 for (t=0; t<nclass; t++) { 
  setForegroundColor(0,0,0);  
  setBackgroundColor(255,255,255);  
  tit = toString(t); 
  selectWindow(tit); 
 
// ...the macro select circles, with the appropriate diameter, centered on 
every single pixel of the active zone and fill them, obtaining the area 
inside the set  max distance from active zone.  
 
      for (i=0; i<xx.length; i++) { 
       run("Specify...", "width="+limite[t]+" 
height="+limite[t]+" x="+xx[i]+" y="+yy[i]+" oval centered"); 
   fill(); 
   showProgress(i/xx.length); 
  } 
  setThreshold(1, 255); 
  run("Convert to Mask"); 
 
// the macro sums images of current sampling zone and vescicles in a new 
image. Only pixels which mark vescicles outside of the sampling area appear 
isolated. 
 
  imageCalculator("Add create", "V",tit); 
  rename("G"); 
   
// 1. Counts the number of isolated pixels (external vescicles) in the new 
image 
 
  run("Analyze Particles...", "size=0-1 circularity=0.00-1.00 
show=Nothing clear record"); 
 
// 2. Vescicles in the zone under analysis are obtained subtracting 
external vescicles from remaining vescicles (at start remaining vescicles = 
initial vescicles). 
 
  totves[t] = LeftVesc - nResults; 
  finves = nResults; 
 
// 3. Counts all the vescicles so far counted in zones 
 
  sommatotves = 0;   
  for (k=0; k<t+1; k++) { 
   sommatotves = sommatotves + totves[k]; 
  } 
 
// 4. Set remaining vescicles as initial vescicles minus the vescicles so 
far counted in zones 
 
  LeftVesc = Initvesc - sommatotves; 
  close(); 
 }  
  
 
// Write results on file 
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 print(results, "Vescicles between 0 e "+up[0]+" nanometers from the 
active zone: "+totves[0]+"\n"); 
 for (t=0; t<nclass-1; t++) { 
  print(results, "Vescicles between "+up[t]+" and "+up[t+1]+" 
nanometers from the active zone: "+totves[t+1]+"\n"); 
 }  
 if (nclass > 0) { 
  print(results, "Total vescicles beyond "+up[t]+" nanometers 
from the active zone: "+finves+"\n");  
 } 
 else { 
  print(results, "Total vescicles external to the active zone: 
"+finves+"\n");  
 } 
 
// Closing result file and working images. End of the macro 
 
 File.close(results); 
 
 selectWindow("S"); 
 close(); 
 selectWindow("V"); 
 close(); 
 for (i=0; i<nclass; i++) { 
  selectWindow(i); 
  close(); 
 } 
 
 setBatchMode(false); 
 
 showMessage("End of Analysis"); 
} 
 
 
4.5 Statistical analyses 
 
All the data collected were finally analyzed with the statistical software Prism 4.0 and 
refers to six animals for each experimental point the total number of observation is reported in 
the text. 
Differences in the onset of pathological symptoms between groups of animals were 
evaluated with the Kaplan-Meier analysis.  
Intergroup comparison of any morphometric parameter were evaluated using the two tailed 
unpaired Student’s t test. Data are expressed as mean  standard deviation; intergroup 
comparison was also pursued with one-way analysis of variance followed by the Bonferroni 
post-hoc test and gave the same results.  Significance threshold was set at p<0.05.  
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5. RESULTS 
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5.1 Innervations of skeletal muscle fibers 
 
Neuromuscular junctions are chemical synapses formed by a presynaptic terminal 
(MN) and by a postsynaptic element, the muscle fiber. We have characterized the 
innervations of NMJs using an immunofluorescence approach, to obtain these results we have 
taken small bundles of muscle fibers (diaphragm) or cryostat sections of the muscle (soleus 
and gastrocnemius). The samples were then stained with TRITC-conjugated -bungarotoxin, 
in this way all the Achetylcholine receptor clusters on the postsynaptic membrane were 
labelled (Fig.1A and C BuTX). Innervation was determined using antibodies direct against 
presynaptic markers such as synaptotagmin1 or synapsin1. An innervated NMJ shows a 
labelling for presynaptic proteins (Fig.1A -syn) that perfectly colocalizes with the 
postsynaptic staining (Fig.1A merge), while, in a denervated NMJ the staining for the 
presynaptic compartment is lost as reported in Fig.1C -syn. The BuTX labeling revealed in 
both the innervations states that clusters of AChRs had the typical pretzel-like shape. 
At the ultrastructural level innervated and denervated NMJ are easily distinguishable: 
in innervated NMJ (Fig.1B) the presynaptic terminal, containing synaptic vesicles and 
cytoplasmatic organelles, lie in shallow primary folds on the membranes of muscle fibers and 
the entire synapse is isolated by processes of Schwann cells that play a structural and 
functional role in the manteinence of neurotransmission.  
In denervated NMJ (Fig.1D) the presynaptic button is lost, the primary fold is flattened while 
the secondary folds are preserved, processes of Schwann cells and collagene fibers cover the 
empty space over the cluster of receptors. 
 We used these approaches to evaluated the percentage of innervations in skeletal 
muscles both at early stage of the pathology (the clinical onset – P85-P90) and at the end 
stage (P140). Our results indicated that the denervation process affect differently the muscles 
that we have analyzed muscles infact, the soleus muscle is completely innervated at the early 
stage of the disease (Fig.2 B), while just a small amount of fibers are denervated at the end 
stage (20% - Fig.2B), over a majority of fibers that didn’t show any phenotype (Fig.2A). 
 In our experimental model the diaphragm is more affected than the soleus and the 
gastrocnemius at P85-95, infact we observed that about 30% of fibers were denervated in 
transgenic mice compared to control ones, the percentage of innervations is further reduced at 
the end stage to the value of 46.5%. whereas gastrocnemius that is more resistant at the 
clinical onset (81% of fibers are innervated) is drastically denervated at the end stage (12% of 
innervations) (Fig.2C). 
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 The intermediate response to the degeneration observed in diaphragm muscle that 
could reflect its mixed fibers composition is the reason because we chose to further 
investigate the ultrastructure of this muscle. 
 
5.11 Characterization of the presynaptic terminal  
 
Mitochondrial pool 
 
Mitochondrial pool represent one of the primary target of ALS-induced damage in the 
presynaptic terminal of motor neuron, features of alteration such as vacuolization, swelling 
and disorganization of cristae, appear early before the beginning of the denervation process. 
(Duffy et al., 2011).  
Alteration in those organelles are deeply characterized both in cellular cultures and in spinal 
cords of rodents l (Raimondi et al., 2006; Jaarsma et al., 2001), but to date only few papers 
were published reporting their ultrastructural characterization in the neuromuscular junctions 
(Dupuis et al., 2009).  
Here we performed a morphological and morphometric analysis of the mitochondrial 
pool both in WT and mSOD1 to clarify mitochondrial involvement in the early stage of 
degeneration of motor neuron associated with ALS.  
In diaphragm NMJs of WT mice each presynaptic button contains one to five 
mitochondria/m2 as reported in Fig. 3B and the total area of mitochondrial pool occupied 
about 23% of the presynaptic terminal area (Fig. 3E), mitochondria were round in shape, with 
continuous inner and outer membranes and slightly electron dense matrix (Fig.3A and inset), 
while in mSOD1 mice were present two different populations of mitochondria in diaphragm: 
intact and altered. 
The number of mitochondria and their density within the synaptic button did not 
change significantly between CTRL and mSOD1 mice (Fig. 3 B and E). 
In the diaphragm of mSOD1 mice about the 60% of presynaptic buttons contained 
mitochondria, which had an aspect comparable with the one of mitochondria in CTRL mice 
(Fig. 3C and inset; Fig. 3F), while in the remaining 40% of NMJ  mitochondria showed 
discontinuity of both the inner and the outer membranes and a pale matrix (Fig. 3D and inset; 
Fig. 3F).    
 Altered mitochondria were swollen and in some cases vacuolization phenomena were 
present, these alteration induce an increase of the average area of mitochondria (0.18 m2 ± 
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0.10) compare to intact (0.13m2 ± 0.05 p = 0.016) and to control (0.11 m2 ± 0.04 p < 
0.0001) ones (Fig. 3G). Despite these results we did not observe alteration of other parameters 
such as circularity index (value of ratio between area and perimeter of mitochondria as 
reported in Akao et al., 2003) (CTRL 0.89 ± 0.05; n = 76; mSOD1 intact 0.86 ± 0.13; n = 37; 
mSOD1 altered 0.85 ± 0.11; n = 33. Fig. 3H).  
At the pathological end stage mitochondrial pool was even more affected, at the 
ultrastructural level both inner and outer membranes were completely disorganized (Fig. 4A 
and inset). Moreover we observed a reduction in the number of mitochondria (between 0.2 
and 2.3 mitochondria/m2; n = 11) compare with what observed in NMJ of mice sacrificed at 
the clinical onset. This phenomenon was accompanied by the reduction of the total size of 
mitochondrial pool (12% of the presynaptic area; n = 11; Fig. 4C). The percentage of 
neuromuscular junctions which showed altered mitochondria was increased in these mice 
compared to the younger ones (72.7%; n = 11; Fig. 4D). 
Moreover the mitochondrial area in mSOD1 mice at the end stage is also broader  (0.34 m2 
± 0.29) than what observed in mSOD1 mice at the clinical onset of the disease. 
 
Synaptic vesicles pool 
 
It has been proposed that alteration in synaptic vesicles pool could be an early 
contributor to muscle weakness in motor neuron diseases (Kong et al., 2009), so we focused 
our attention in the analysis of synaptic vesicles density within the nerve ending of MNs using 
the Imagej tool as reported in Material and Method chapter. 
In Fig. 5 is reported a representative micrograph of nerve ending button analized with 
this approach  (Fig.5A) and the mask that the software generated in which each synaptic 
vesicle is pointed in its centre and the presynaptic membrane is labelled with a 10 pixels-thick 
line (Fig. 5B). 
Panel C in the same figure indicates how the software works: starting from 
magnification and resolution of each image, the mask was analyzed and data related to the 
number and the distribution of synaptic vesicles was extrapolated.
 
In NMJ of mSOD1 mice we observe a significant reduction in the total amount of SV 
(125.4/m2 ± 80.1) compared to CTRL group (220.3/m2 ± 112.6 p= 0.0035) (Fig. 5D). 
Although in mSOD1 presynaptic terminals the morphology of synaptic vesicles did not differ 
from those observed in CTRL samples and the reduction did not correlate with number or the 
state of mitochondria within the same button. 
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We next examined the distribution of synaptic vesicles according to their distance 
from presynaptic plasma membrane, to this aim we classified vesicles as: docked vesicles (0-
20 nm from the plasma membrane), vesicles located within 200 nm and vesicles located 
beyond 200 nm from the plasma membrane.  
We did not find any significant difference in SV distribution comparing WT NMJs 
(10.4//m2 ± 7; 75.7/m2 ± 50.6; 134.2/m2 ± 63.4) with mSOD1 (8.2/m2 ± 6.3; 63.6/m2 ± 
40.3; 90.1/m2 ± 55.9) ones (Fig. 5E), nor difference in the synaptic vesicle pool organization 
between mSOD1 terminals containing intact or altered mitochondria. For the evaluation of 
SV distribution 12 buttons were analyzed for each experimental point. 
 
5.12 Characterization of the postsynaptic element 
 
Skeletal muscle fibers 
 
For the evaluation of fibers diameter we used both coronal and longitudinal sections of 
skeletal muscle inclusions (Fig. 6 A e B), of WT and mSOD1 mice at the clinical onset of the 
disease. 
Muscles analyzed, the soleus, the diaphragm and the gastrocnemius, showed different 
response to the pathological condition:  
 
 
 
For the further understanding of these differences we divided fibers in size classes thin 
fibers (diameter < 20 m), medium fibers (20 m < diameter < 30 m) and thick fibers 
(diameter > 30 m). 
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Clusters of ACh receptors  
 
Then we then focused our attention on the evaluation of the size and the architecture 
of the  clusters of acetylcholine receptors (AChR) in the postsynaptic membrane.  
In IF experiments (see the chapter of Material and Method, paragraph of 
‘Fluorescence and Immunofluorescence Analysis’) we collected z-series of images of AChR 
clusters, labelled with TRITC-conjugated BuTX (Fig. 7 A and C) and the measure of the total 
area of the cluster was performed on maximun projection after the application of an intensity 
threshold (Fig. 7 B and D). 
In the diaphragm of CTRL animals, the mean area of AChR cluster is 360.75 m2 ± 
126.97   (n = 92; Fig. 7E) compared to 429.53 m2 ± 119.38 (n = 62) of mSOD1 mice, the 
same increased was observed in the gastrocnemius were the clusters size increased from 297.8 
m2 ±120.1 (n = 10) of CTRL muscles up to 352.6 m2 ± 96.16 (n = 10) of mSOD1 ones.  
Moreover we evaluated if the innervations state of NMJ had any relevance in this 
increase so we divided innervated junctions from the denervated ones. 
The denervated junctions of mSOD1 diaphragm shown a broader BuTX-positive area 
(452.2m2 ± 113.3; n = 21) compared to innervated junctions of transgenic mice (418.2 m2 
± 107.6; n = 34) and also compared to NMJs of control muscle (Fig. 7E). 
We also evaluate the size of clusters in the gastrocnemius in samples stained just with 
BuTX and our results indicated that the mean BuTX-positive surface is broader in mSOD1 
mice compared with CTRL ones (CTRL 297.8m2 ±120.1; n =10; mSOD1 352.6 m2 
±96.16; n = 10; p = n.s.). 
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5.2 Nandrolone administration 
 
In the second part of this project we performed a study of effectiveness of a 
pharmacological treatment with the steroid nandrolone decanoate.  
This drug is employed in the treatment of those pathologies that induce wasting of 
skeletal muscles (Sardar et al., 2010).  
In rodents it has been demonstrated that nandrolone is able improve respiratory 
functions in rodents, improving the force and the strength of respiratory muscles (including 
diaphragm) more efficiently than with inspiratory muscle training (Gayan-Ramirez et al., 
2000). 
  
5.21 Characterization of the presynaptic terminal in treated mice 
 
Mitochondrial pool 
 
 We then analyzed, using the same morphological and morphometric parameters, the 
characteristics of the mitochondrial pool in the presynaptic terminal of innervated 
neuromuscular junctions of treated mice and we compared these results with those obtained in 
the previous analysis. 
 The architecture of mitochondria in the presynaptic terminal was rescued in treated 
mSOD1 mice compared with untreated and the percentage of altered mitochondria (9%) 
gained levels comparable with CTRL animals (Fig. 8A). 
 Our observations indicated that altered mitochondria in NMJ of treated mice had a 
broader area (0.203 m2 ± 0.13; n = 23), compared with intact mitochondria belonging to the 
same class (0.113 m2 ± 0.075; n = 45; p = 0.0055), while there were not differences neither 
between area of intact mitochondria belonging to different classes nor to altered ones (Fig. 
8B). 
 Circularity index did not change between treated and untreated mice (treated mSOD1 
intact 0.83 ± 0.12; n = 45; altered 0.74 ± 0.15; n = 23; p = n.s.) nor between intact and altered 
mitochondria belonging to different class of mice (Fig. 8C). 
 Moreover there was no difference in the density of mitochondria within the 
presynaptic button comparing treated and untreated mice (mSOD1 NAN – 1.987 n/m2 ± 1.3; 
n = 12; mSOD1 NAN + 1.96 n/ m2 ± 0.99; n= 11) (Fig. 8D). 
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Synaptic vesicles pool  
 
 Treatment with nandrolone exerted also an effect in the density of synaptic vesicles, 
the total number of SV was reduced in treated mice (92.69 n/m2 ± 56.73; n = 18) compared 
with untreated ones (Fig. 8E), but this reduction is more evident in pools of vesicles closer to 
the presynaptic membrane (mSOD1 treated mice docked vesicle 2.4 n/m2 ±  3.5; between 20 
and 200 nm 33.71 n/m2 ± 22.34;  beyond 200 nm 64.74 n/m2 ± 48.02; n = 11) compared to 
untreated animals (Fig. 8F). 
 
5.22 Characterization of the postsynaptic element in treated mice 
 
Skeletal muscle fibers 
 
The evaluation of fibers diameter in mSOD1 mice indicated that nandrolone was able 
to induce an increase of this value both in diaphragm (37.24m ± 7.64; n = 304; p < 0.0001) 
and in gastrocnemius (45.75m ± 13.87; n = 104; p < 0.0001) compared to the respective 
muscles of untreated mSOD1 mice (Fig. 9A). 
 As we did for control mice we also divided muscular fibers in classes related to their 
diameter. (Fig. 9B).  
 
 
 
Clusters of ACh receptors  
 
Next we examined the architecture of cholinergic receptor clusters in treated mice as 
we did for those of untreated ones. The shape and the complexity of cluster did not change 
between treated and untreated mice neither in the diaphragm nor in the gastrocnemius. The 
mean area of clusters in the gastrocnemius of treated mice was broader than what observed in 
untreated muscle (NAN- 352.6m2 ± 96.16; n = 10; NAN+ 644.6m2 ± 92.85; n = 10; p = 
0.017). In the diaphragm we deeper investigated this phenomenon in IF samples so we 
divided innervated and denervated junctions. Our results indicated that nandrolone 
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administration is sufficient to induce an increase of this value both in innervated (538.2 m2 ± 
160.8; n = 27; p = 0.005) and denervated (496.4 junctions. m2 ± 127.5; n = 23; p = n.s.) as 
well as in CTRL animals (410.56m2 ± 116.11; n = 93; p = 0.0059; Fig. 9C and table).  
 
 
 
 
5.3 Percentage of innervated fibers and clinical onset of the disease in 
treated mSOD1 mice 
 
 The evaluation of percentage of innervated fibers was made both in diaphragm and in 
gastrocnemius muscle of treated mice, at the clinical onset of the disease, our data indicated 
that nandrolone administration induced a slight increase of the number of innervated fibers in 
diaphragm (76.33%) compared to untreated ones, while the effect is mor pronounced in 
gastrocnemius muscle where the percentage is completely rescued to control level (100%; 
Fig. 10A )  
In our experimental model the percentage of innervations showed a great variability in 
the diaphragm (Fig. 10B), moreover the partial rescued of this value in treated mice was not 
enough neither to delay, nor to prevent the clinical onset of the pathology (Fig. 10C). 
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6. DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
55 
 
The first part of this study is focused on the anatomical characterization of motor units 
and, particularly, on the morphological alteration induced by the ALS phenotype. In this 
project we use SOD1 G93A mice (Gurney et al., 1994) as model of a familial form of ALS. 
This is the first time that NMJs of the murine diaphragm were analyzed at an ultrastructural 
level in this model of ALS, moreover we investigated both the clinical onset of the disease 
and the pathological end stage to evaluate sings of disease progression. 
Our data indicate that different muscles behave differently, in fact the diaphragm and 
the gastrocnemius show a slight percentage of denervated fibers at the clinical onset and a 
more severe condiction at a later stage, while the soleus is completely innervated at the early 
stage and shows just a small amount of denervated fibers at P140, this phenomenon is due 
probably to the differential MU composition of these muscles (Frey et al., 2000) In this work 
we focused our attention on the diaphragm because of its role in the death of ALS patients. 
Treatment with nandrolone preserved the diaphragm muscle mass and reduced mitochondrial 
damage in nerve endings, but did not significantly increase the number of innervated 
diaphragm fibers. In the gastrocnemius, where we did not observe ALS-induced reduction of 
fibers size, nandrolone administration is sufficient to induce fiber hypertrophy, which is 
probably due to the proliferation of satellite cells (Allouh and Rosser, 2010).   
 
Presynaptic terminals innervating the diaphragm exhibit structural alterations in mSOD1 
mice at early symptomatic stage  
 
By analyzing the fine structure of mitochondrial pools in presynaptic terminals of 
NMJs of mSOD1 mice, we here provide evidence of alterations of mitochondria, which 
exhibited disorganization of cristae in about 40% of presynaptic profiles, this morphological 
index of alteration is evenmore pronounced at the pathological end stage indicating that 
mitochondrlia degeneration, which is an early effect in ALS, proceeds during all the 
degenerative process. In thin sections, the profiles of these mitochondria were significantly 
broader than those of intact mitochondria in NMJs of both mSOD1 and wild-type mice. Other 
parameters, such as circularity and density, did not differ between mitochondria of mSOD1 
and wild-type NMJs.  
Mitochondria are considered one of the major intracellular targets of mSOD1 toxicity 
in motoneurons (Kong and Xu, 1998; Liu et al., 2004), and several studies have reported 
alterations in their functionality (Mattiazzi et al., 2002; Ferri et al., 2006), as well as in their 
morphology in neurons and muscles of ALS patients (Siklós et al., 1996; Menzies et al., 
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2002a and references therein; Chung and Suh, 2002). Similarly, swelling, vacuolation and 
alteration in the organization of mitochondrial cristae have been reported in cellular 
(Raimondi et al. 2006; Menzies et al., 2002b) and animal models of this pathology by means 
of ultrastructural analyses of mitochondria in axons and proximal dendrites (Kong and Xu, 
1998; Bendotti et al., 2001) and in motoneuron nerve endings (Gould et al., 2006). The 
present findings in the NMJs of diaphragm of mSOD1 mice support a role for mitochondrial 
alterations in ALS pathogenesis and show that they precede muscle denervation. We also 
found that the synaptic vesicle density was significantly reduced in mSOD1 terminals 
compared to wild-type ones, with no significant changes in their distribution in the 
presynaptic terminal. Reduction in the number of synaptic vesicles has been previously 
observed with immunofluorescence in NMJs of locomotor skeletal muscle of mSOD1 mice, 
and it has been interpreted as a consequence of impaired vesicle transport in the axons of fast 
fatiguable motoneurons (Pun et al., 2006).  
In the murine model of a different neuromuscular disease, spinal muscular atrophy 
(SMA), the pool of neurotransmitter-containing vesicles in nerve terminals of motoneurons is 
affected in both size and distribution, indicating that decreased vesicle availability could 
account for impaired neurotransmission and NMJs dysfunction in SMA (Kong et al., 2009). 
Thus, similarly to the SMA model, the present findings indicate that defects in 
neurotransmission may contribute to NMJs dysfunction and lead to denervation. Interestingly, 
we did not find a relationship between synaptic vesicle pool size and mitochondrial changes 
in the presynaptic terminals of mSOD1 NMJs. The independence between these parameters is 
further supported by the findings, discussed below, that nandrolone treatment exerted an 
effect on mitochondrial changes but not on the synaptic vesicle pool size. 
 
Effect of nandrolone treatment 
 
Treatment of mSOD1 mice with nandrolone during the presymptomatic stage of 
disease was here found to prevent loss of diaphgram muscle mass. In particular, our data 
indicate that nandrolone, while having no major effect on the size of diaphragm muscle fibers 
in wild-type mice, exerted a trophic effect by restoring fiber size to control value in mSOD1 
mice. 
Concerning the lack of effect in wild-type mice, it should be considered that continuous 
administration of nandrolone increases the cross-sectional area of fibers in the innervated rat 
diaphragm (Lewis et al., 1999), but this effect did not occur when the administration of high 
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doses of the drug was intermittent (Bisschop et al., 1997), as in the present paradigm. As for 
mSOD1 mice, it is worth recalling that gene expression profiles studies have shown that the 
effect of nandrolone in preventing denervation-induced atrophy may vary depending on the 
time of denervation (Zhao et al., 2008; Qin et al., 2010). Interestingly, in our study the 
reduction in the mean diameter of muscle fibers in untreated mSOD1 mice implicated the 
appearance of very thin fibers with increase of a subpopulation of fibers thinner than in wild-
type mice. In nandrolonetreated mSOD1 mice the distribution of fibers according to their 
diameter was similar to that documented in wild-type littermates. Therefore, given the 
denervation of some muscle fibers in mSOD1 mice, it can be hypothesized that nandrolone 
acts on fibers that underwent denervation by fuelling/supporting their metabolism and thus 
preventing atrophy, with no detectable effects on innervated fibers.  
Treatment with nandrolone equally affected the synaptic vesicle pool density of wild-
type and mSOD1 mice, with a significant decrease in the mean number of docked vesicles 
and vesicles within 200 nm in the latter mice. This reduction in the number of vesicles 
actively involved in neurotransmitter release could reflect a potentiation of synaptic 
neurotransmission induced by steroid administration (Blanco et al., 2001), an effect here 
observed in both wild-type and mSOD1 mice. Such effect could be further strengthened by 
the parallel increase in the total surface area of AChR clusters in the muscle fiber induced by 
nandrolone administration in both genotypes. In the rat skeletal muscle, androgen receptors 
are preferentially accumulated in myo-nuclei located under the NMJ where they may 
specifically control the expression levels of synapse-related proteins (Monks et al., 2004).  
The fine structure of presynaptic terminals in nandrolone-treated mSOD1 muscles 
revealed that the number of presynaptic profiles containing damaged mitochondria was 
reduced to control values. This observation suggests that nandrolone may exert a protective 
effect on NMJs by protecting motoneuron mitochondria. Altogether such findings point to a 
synaptic effect of nandrolone treatment that involves both the mitochondrial pool and 
synaptic vesicle dynamics. This raises the possibility that either nandrolone acts directly on 
motoneuron terminals (which express androgen receptors) or this effect is mediated by other 
trophic factors produced by the muscle fiber in response to treatment. In fact, it has been 
demonstrated that nandrolone administration increases the levels of muscle insulin growth 
factor-1 mRNA (Gayan-Ramirez et al., 2000) and protein (Lewis et al., 2002) in the 
diaphragm of rats, and that muscle-specific expression of local insulin growth factor-1 
stabilizes NMJs in mSOD1 mice (Dobrowolny et al., 2005) delaying disease onset and 
progression. However, the present findings also show that chronic nandrolone treatment does 
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not exert significant effects in protecting muscle fibers from denervation. An assessment of 
the potential effect of nandrolone on survival of mSOD1 mice was behind the scope of the 
present work also considering the fact that, to date, the majority of the results obtained in 
therapeutic studies on the SOD1 G93A mouse model based on survival analyses have not 
been consistently reproducible due to high variability caused by confounding variables (Scott 
et al., 2008). On the other hand, it cannot be excluded that respiratory muscles could behave 
differently from locomotor muscles with respect to activity-dependent damages and drug 
susceptibiliy even though no specific effects on muscle mass have been observed among 
different muscle types, including diaphragm, upon nadrolone treatment (Bisschop et al., 
1997). Taken together the present results suggest that the integrity of the mitochondrial pool 
in motoneuron nerve terminals, which was preserved by nadrolone treatment, is a necessary 
but not sufficient condition to prevent denervation of mSOD1 muscles. 
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7. FIGURES AND LEGENDS  
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Fig. 1 Anatomical and ultrastructural characterization of innervated and denervated 
neuromuscular junctions 
 
A: Representative confocal image of an innervated neuromscular junction (NMJ) in 
diaphragm muscle of P85-P95 mice. 
The BuTX panel shows the cluster of AChR in the postsynaptic membrane obtained with 
TRITC-conjugated -Bungarotoxin, the architecture of clusters has the usual pretzel-like 
shape.  
The -synapsin panel represents the immunostaining for the presynaptic marker synapsin1 
made through the staining with a polyclonal antibody against the protein and the successive 
staining with a secondary antibody -rabbit conjugated with Alexa-488. (Scale bar: 10 m) 
 
B: Representative EM micrograph of innervated junction in the diaphragm of P85-P95 mice. 
The presynaptic button lies over a shallow primary fold and Schwann cells processes cover it, 
the nerve terminal is filled with cytoplasmatic organelles (mainly mitochondria) and synaptic 
vesicles (SV). 
Beneath the synaptic cleft the postsynaptic membrane is specialized into secondary folds that 
show an electron dense basal membrane. (Scale bar: 500 nm) 
 
C: Confocal image of a denervated NMJ in diaphragm muscle of P85-P95 mice. 
The IF approach used is the same of the A line, despite there are no alterations neither in the 
complexity nor in the shape of the AChR cluster in the postsynaptic membrane, the lack of 
the presynaptic staining reveals the denervation of this junction. (Same magnification of the A 
line) 
 
D: Electron microscopy image of a denervated NMJ in the diaphragm of P85-P95 mice. 
At the ultrastructural level, the presynaptic button is absent in denervated junctions, the 
primary fold is flattened, Schwann cells processes and collagen fibers cover the postsynaptic 
element. 
There is not any alteration, neither in the length, nor in the ramification of secondary folds. 
(Same magnification of B line) 
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Fig. 2 Pathological progression in skeletal muscles 
 
A: EM micrograph of an innervated NMJ in the soleus of end stage mSOD1 mouse.  
Soleus muscle shows a higher plasticity in ALS development, at the end stage (P140) of the 
disease NMJs are almost completely innervated and there are no sings of ALS-induced 
alterations in the ultrastructure of presynaptic buttons, mitochondrial pool or synaptic 
vesicles, primary fold is preserved as well as secondary folds, Schwann cells processes isolate 
the synapse. (Scale bar: 1m) 
 
B: Evaluation of percentage of innervated fibres in the soleus, the diaphragm and the 
gastrocnemius both at the clinical onset (P85-P95) and at the end stage (P140). The graph 
shows values of innervated fibers evaluated with both IF and EM approaches and normalized 
for the percentage of innervation of control muscles at the clinical onset of the disease. 
At P85-P95 the soleus of mSOD1 mice is entirely innervate while, at the same time point, 
denervation process starts in the diaphragm (72.53% of innervated fibers) and in the 
gastrocnemius (81.15% of innervated fibers). At the end stage of the disease the percentage of 
innervation is further reduced both in soleus muscle (80%), in the diaphragm (46.51%) and in 
the gastrocnemius that is almost completely denervated (11.99%). 
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Fig. 3 Morphological and morphometric analysis of mitochondrial pool (P85-P95) 
 
A: Representative EM micrograph of mitochondrial pool within the presynaptic terminal of 
an innervated NMJ in the diaphragm of P85-P95 CTRL mice. Each mitochondrion in the 
buttons of innervated junction has a round profile, continuous inner and outer membranes, a 
slight electron dense matrix and mitochondrial cristae are well organized. In the inset is 
reported an example of mitochondrial ultrastructure at a higher magnification. (Scale bars: 
EM 500 nm, inset 200 nm)   
B: Number of mitochondria in NMJ. At ALS clinical onset, in diaphragm muscle of mSOD1 
mice the total number of mitochondria within the presynaptic terminal does not significantly 
changes (1.99  1.33 mitochondria/m2; n = 12) compared with whose of CTRL synapses 
(2.49 ± 1.11 mitochondria/m2; n = 15).  
C and D: qualitative analysis of mitochondria into innervated junctions of diaphragm of 
mSOD1 mouse (P85-P95). In the presynaptic terminal of mSOD1 synapses two population of 
mitochondria have been observed in C panel the mainly phenotype of mitochondria which 
have the same aspect of ones observed in CTRL NMJ. In the D panel is reported an example 
of altered mitochondria that are characterized by fragmented inner and outer membranes, 
disorganized cristae scattered into a pale mitochondrial matrix. Some mitochondria are 
associated with outer membrane vacuolization phenomena (arrowheads). (Scale bars: 
EM 500 nm, inset 200 nm)   
E: The percentage of the presynaptic area occupied by the mitochondrial pool is slightly 
reduced in mSOD1 mice (19.48% ± 12.67; n = 12) compared with CTRL ones (23.06% ± 
8.30; n = 15). The difference is not statistically significant.  
F: Number of NMJ that contain more than 50% of altered mitochondria. This value varies in a 
significantly manner between CTRL group (0% of alteration) and mSOD1 one (40% of 
alteration). 
G: Average area of mitochondria. Mitochondria of CTRL (0.108 m2 ± 0.04; n = 76) 
synapses are smaller than what observed in mSOD1 synapses, in both the intact class of 
mitochondria (0.13 m2 ± 0.05; n = 37; p = 0,0036) and in altered one (0,18 m2 ± 0.1; n = 
33; p < 0.0001). 
H: Evaluation of circularity index. There are no differences between CTRL group and 
mSOD1 one. 
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Fig. 4 Morphological and morphometric analysis of mitochondrial pool (P140) 
 
A: Representative image of presynaptic terminal of mSOD1 diaphragm at the pathological 
end stage (P140). Altered mitochondria show the same phenotype of those observed at the 
clinical onset of the disease, mitochondrial cristae are scattered and the empty mitochondrial 
matrix is pale (inset), moreover fragmented membranes and vacuolization phenomena 
(arrowheads) are standard features of the mitochondrial pool in this experimental group 
compared with CTRL and mSOD1 at the clinical onset. (Scale bars: EM 500 nm, inset 200 
nm) 
 
B: The number of mitochondria into synaptic buttons is further reduced in P140 mSOD1 mice 
(0.734 0.6 mitochondria/m2; n = 11) compared to the ones sacrificed at the clinical onset. 
 
C: Even the percentage of area occupied by the mitochondrial pool into the nerve ending is 
reduced at the pathological end stage (12.7%  9.2; n = 11), compared with P85-P95 animals. 
 
D: The percentage of NMJs containing more than 50% of altered mitochondria is increased in 
this animals (72,7%) compared with all the other experimental groups.  
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Fig. 5 Density and distribution of synaptic vesicles into the presynaptic terminal 
 
 
A and B: Representation of the mask generation. In each EM micrograph (A) analyzed the 
centre of SVs (arrowheads in A) is labelled with a single pixel point (arrowheads in B), and 
the presynaptic membrane (arrow in A) is highlighted by a 10-pixels thick line (arrow in B). 
(Scale bar: 500 nm) 
 
C: Input of the parameter of images acquisition and output of distribution data. The ImageJ 
macro required information of magnification and resolution of the image and the distance 
limit for any class of SVs from the presynaptic membrane. The output data indicated the total 
number of SVs and the number of SVs in the selected classes of distance. 
 
D: Total number of synaptic vesicles in mSOD1 mice (125.4 SVs/m2 ± 80.5; n = 25) is 
significantly reduced at the onset of the disease compared to data obtain in CTRL mice (220.3 
SVs/m2 ± 112.6; n = 15; p = 0.0035). 
 
E: Quantification of vesicle distribution within the presynaptic buttons. There are no 
significant variations in the number of SVs in the selected classes of distance between CTRL 
synapses and mSOD1 ones. 
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Fig. 6 Diameter of muscular fibers 
 
A and B: Representative bright field images of longitudinal and coronal sections of skeletal 
muscle fibers in the diaphragm of CTRL mice. (Scale bars: 10 m) 
 
C: Mean diameter of fibers in skeletal muscles. 
 
 
D, E and F: Subdivision of fibers related to their diameters value. 
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Fig. 7 Analysis o Acetyl Choline Receptor (AChR) clusters. 
 
A and C: Representative confocal images of the AChR clusters in an innervated NMJ of 
diaphragm of CTRL animals (A) and of mSOD1 mice (C). Those images are related with IF 
experiments reported in Fig. 1A and C (Scale bar 10 m). 
 
B and D: Bitmap masks of the same cluster reported in panels A and C 
 
E: Statistical analysis of obtained values indicated that CTRL synapses have a smaller BuTX-
positive area (360.75 m2 ± 126.97; n = 92) compared with mSOD1 ones both the innervated 
(418.2 m2 ± 10.6; n = 34; p = 0.02) and denervated ones (452.2m2 ± 131.3; n = 21; p = 
0.0014). 
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Fig. 8 Nandrolone-mediated effects in presynaptic terminal 
 
A: Number of NMJ that contain more than 50% of altered mitochondria. The value of NMJ 
containing intact mitochondria is rescued in treated mSOD1 mice (91% of NMJ with intact 
mitochondria) at the same level than what observed in CTRL mice. 
 
B: The mean area of intact mitochondria in innervated NMJ of treated animals is slight 
reduced compared to untreated mice (0.113 m2 ± 0.075; n = 45; p = n.s.) while is increased 
in altered ones (0.203  m2 ± 0.134; n = 23; p = n.s.). Both intact and altered 
mitochondria of treated muscles show a broader area compared to untreated ones of the same 
class (untreated intact/untreated altered p = 0.016; treated intact/treated altered p = 0.0055). 
 
C: Even in this case there are no variations in the value of circularity index. 
 
D: The total number of mitochondria reported to the area of presynaptic terminal does not 
change between untreated and treated mSOD1 (untreated 1.99/m2; treated 1.97/m2). 
 
E: Total number of synaptic vesicle in the presynaptic terminal. This value does not change 
significantly between untreated and treated mice (92,69/m2 ± 56.73; n = 18; p = n.s.). 
 
F: The distribution of SV indicates a reduction in number of SV in the docked pool of treated 
mice (2.34/m2 ± 3.51; n = 11; p = 0.0132) compared to untreated ones. Moreover even in the 
number of SV distributed within 200 nm from the plasmamembrane the reduction is 
statistically significant between untreated and treated (33.71/m2 ± 22.34; n = 11; p = 0.04) 
NMJ. While no significant variation in the distribution of SV beyond 200 nm is observed 
between untreated and treated mice. 
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Fig. 9 Nandrolone-mediated effects in postsynaptic elements 
 
A: Fibers diameter evaluation in skeletal muscles of treated mice. 
 
 
B: Subdivision of fibers related to their diameters value. 
 
 
C: Quantification of AChR clusters in the diaphragm of treated mice. 
Nandrolone administration induced an increase of the size of AChR clusters in each 
experimental group: 
 
In CTRL group the difference between treated and untreated mice is statistically significant (p 
= 0.0059), the average BuTX positive area is broader in treated innervated NMJ compared to 
untreated ones (p = 0.005) in a statistically significant manner, even in denervated junction 
treated with nandrolone there is an increaser of clusters area while this difference is not 
significant. 
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Fig. 10 Percentage of innervated fibers and disease clinical onset in treated mice 
 
 
A: The mean value of innervation is evaluated in both the diaphragm and the gastrocnemius at 
the clinical onset of the disease. There is a slight increase of the percentage of innervated 
fibers in treated mSOD1 diaphragm (76.3%) compared to untreated one (71.8%), in 
gastrocnemius muscle the effect of nandrolone administration rescues completely the value at 
the CTRL level (100%). 
 
B: The percentage of innervation is evaluated in each mouse and we observe a great 
variability between animals especially in mSOD1 mice both treated and untreated ones. 
 
C: The Kaplan-Meier analysis reveals that there are no significant variation in the age of onset 
of the disease between treated and untreated mice. 
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Abbreviations 
 ACh Acetylcholine 
 AChR Acetylcholine Receptor 
 ALS Amyotrophic Lateral Sclerosis 
 ALS2 Alsin2 
 AMPA 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid 
 ANG ANGiogenin 
 ATP/GTP Adenosine/Guanosin Tri-Phosphate 
 BS Blocking Solution 
 BuTX -BungaroToXin 
 CNS Central Nervous System 
 COPD Chronic Obstructive Pulmonary Disease 
 CSA Cross Sectional Area 
 CTRL Control 
 DeSyn Delayed Synapsing 
 DNA DeoxyriboNucleic Acid 
 EAAT Excitatory AminoAcid Transporter 
 EM Electron Microscopy 
 fALS Familial Amyotrophic Lateral sclerosis 
 FaSyn Fast Synapsing 
 FDA Food and Drugs Administration 
o FF Fast Fatigable 
o FI Fast fatigue Intermediate 
o FR Fast Fatigue-Resistant 
o S Slow 
 FIG4 PI(3,5)P(2)5-Phosphatase 
 FTD FrontoTemporal Dementia 
 FUS FUsed in Sarcoma 
 GDNF Glial-cell-line Derived Neurotrophic Factor 
 GLT GLial Glutamate Transporter 
 HDAC Histone DeACetylase 
 HIV Human Immunodeficency Virus 
 hSOD Human SuperOxide Dismutase 
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 IGF Insulin-like Growth Factor 
 IMT Inspiratory Muscle Training 
 KO Knock Out 
 LMN Lower MotoNeuron 
 MHC Myosin Heavy Chain 
 MN MotoNeuron 
 MND MotoNeuron Disease/Disorder 
 mRNA Messanger RiboNucleic Acid 
 mSOD Mutant SuperOxide Dismutase 
 MU Motor Unit: 
 NAN NANdrolone decanoate 
o NAN– Untreated 
o NAN+ Treated 
 NF NeuroFilament 
 NMDA N-Methyl-D-aspartate 
 NMJ NeuroMuscular Junction 
 OCT Optimal Cutting Temperature 
 PBS Phosphate Buffer Saline 
 PDC Parkinson-Dementia Complex 
 PLS Primary Lateral Sclerosis 
 PMA Progressive Muscular Atrophy 
 RNA RiboNucleic Acid 
 ROS Reactive Oxygen Species 
 sALS Sporadic Amyotrophic Lateral Sclerosis 
 SETX SEnTaXin 
 SMA Spinal Muscular Atrophy 
 SNP Single Nucleotide Polymorphism 
 SOD SuperOxide Dismutase 
 SPG11 Spatacsin 
 SV Synaptic Vesicle 
 TARDBP TAR DNA Binding Protein  
 TDP TAR DNA binding Protein 
 TEM Transmission Electrom Microscopy 
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 TNF Tumor Necrosis Factor 
 TRITC Tetamethyl-Rhodamine 
 UMN Upper MotoNeuron 
 UPR Unfolded Protein Response 
 VAMP Vesicle-Associated Membrane Protein 
 VAPB/C Vesicle-associated membrane protein-Associated Protein B/C 
 VEGF Vascular Endothelial Growth Factor 
 VPA ValProic Acid 
 WS Washing Solution 
 WT Wild Type 
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